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Executive Summary 
 
Psychological treatments occupy an important place in evidence-based mental health 
treatments. It is an exciting time to fuel treatment research: there is a pressing demand for 
improvements poised alongside new opportunities afforded by closer links with sister 
scientific and clinical disciplines. The needs are great. Even our best treatments do not work 
for everyone, there are many mental health disorders for which treatments have not been 
developed, and the implementation of treatments needs to address worldwide scalability. 
Meanwhile, psychological treatments are yet to benefit from numerous recent innovations in 
science, and arguably vice versa. This Commission is comprised of ten parts that each outline 
an area in which we see significant opportunity and scope for advancements that will move 
psychological treatments research forward. 
Part 1: Why do existing treatments work? Making the case for mechanisms of psychological 
treatments. Beyond knowing that an intervention is efficacious, we need research initiatives 
that elucidate the key mechanisms through which the intervention effects change. An 
experimental psychopathology approach enables the identification of mechanisms. Research 
on mechanisms has significant scope to faciliate  treatment innovation.  
Part 2: Where can psychological treatments be deployed? Research to improve mental health 
worldwide. We outline a number of factors to facilitate access to psychological treatments 
worldwide. Future research inititatives need to continue to develop and evaluate the efficacy 
of brief, flexible interventions that can be adapted to meet the needs of individuals across 
cultural contexts, delivered and disseminated in a sustainable way. 
Part 3: With what? The potential for synergistic treatment effects: using and developing 
cross-modal treatment approaches. The combination of psychological and pharmacological 
treatments needs to be better understood both in terms of clinical impact and underlying 
shared/different mechanisms. Efforts to develop and investigate the efficacy of novel cross-
modal treatments  may contribute to treatment innovation. 
Part 4: When in life?  Psychological science, prevention and early intervention: getting it 
right from the start. The social and economic toll of mental health problems early in life 
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render the development of effective prevention and early intervention approaches a priority. 
The adoption of both a preventive focus and a developmental approach is needed to identify 
risk factors for psychopathology, as well as the optimal time at which to offer prevention 
approachesto increase the likelihood of setting vulnerable young people on a path to positive 
mental health. 
Part 5: Technology: Can we transform the availability and efficacy of psychological 
treatment through new technologies? New technologies provide exciting and timely means 
by which to disseminate and extend the efficacy and global reach of evidence-based 
interventions. eHealth and mHealth approaches that use information technology (e.g., the 
Internet, virtual reality, serious gaming) and mobile and wireless applications (e.g., text 
messaging, apps) are examples of ways in which technology has been harnessed to innovate 
psychological treatments, their availability and evaluation.  
Part 6: Trials to Evaluate Psychological Therapies. The findings of randomised controlled 
trials that evaluate psychological therapies critically inform policy and practice. Accordingly, 
the design and conduct of RCTs warrant scrutiny and ongoing efforts for quality 
improvement (e.g., reporting standards, specification of protocols and inclusion/exclusion 
criteria, choice of outcome measures, measurement of adverse effects, prevention of bias in 
design and analysis). We outline a number of opportunities for further improvement which 
will ultimately enhance the credibility of quality of trials. 
Part 7: Training: Can we foster a vision for interdisciplinary training across mental health 
sciences to improve psychological treatments? Early examples of collaboration between basic 
scientists and practitioners translated to historical steps in psychological treatment 
innovation. Such synergy is less apparent in more recent years. Improving links between 
clinical psychology, psychiatry, and basic research has the potential to again deliver advances 
in psychological treatments. We propose opportunities to improve training in 
interdisciplinary mental health sciences as an important initial step in forging the links 
between scientists and practitioners in the next generation, in order to bridge the extant gap 
between clinical practice and the basic research programs that underpin psychological 
treatments.  
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Part 8: Who should we treat for what and with what? Embracing the complexity of mental 
disorders from personalised models to universal approaches. Mental health disorders are 
inherently complex (e.g., heterogeneity in symptoms across disorders, high rates of 
comorbidity). Evidence-based treatments must address this complexity. Potential solutions to 
the complexity of mental health disorders include considering both highly individualized 
‘personalised’ approaches as well as ‘universal’/‘transdiagnostic’ approaches that target 
common mechanisms. A goal of future research will be to examine whether these approaches 
improve treatment effectiveness.  
Part 9: Target: Suicidal behaviour: Protecting lives. This topic illustrates one of many areas 
in which advances are needed. Despite recent developments in our understanding of risk 
factors that predict suicide attempts, as well as the treatment and prevention of suicidal 
behaviour, many oustanding questions remain. We specify areas for future research; e.g., use 
of new technologies, the role of culture,input from individuals with lived experience of 
suicidal behaviour, and employing a team science approach in develop, evaluate and 
disseminate prevention efforts. 
Part 10: Trafalgar Square and The Empty Plinth - A space for active innovation and 
scrutiny of psychological treatments research of the future. The task of improving 
psychological treatments presents an exciting prospect for scientists and clinicians with an 
interest in the ‘science of mental life’. Clinicians, researchers, service users, carers, funders, 
commissioners, managers, policy-planners, ‘change’ experts –all have a part to play. Some 
long held ideas need examination, from the branding of psychological treatment types to 
considering what it is that people actually want treatment for. Scrutiny of new ideas should be 
rigorous yet encourage innovation.  
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Introduction [Section type heading] 
Psychology and psychological treatments 
Psychology from its inception was defined as ‘the science of mental life’1. Psychological 
treatments have evolved to occupy a key place in evidence-based treatments for mental 
health. Pivotal techniques used in today’s evidence-based psychological treatments arose 
from psychological research on processes in the 1950s and 1960s, with basic and clinical 
researchers often in the same department. In recent decades the treatment field has drifted 
away from its scientific roots, while mechanistic studies have drifted further away from 
treatment issues. Now is the time for greater synergy to invigorate psychological treatment 
research2. Psychological treatments offer great promise for continued innovation, not least 
owing to the development of scientific methods and perspectives from many allied fields. 
While researchers and industry struggle to produce new drugs for mental disorders, 
psychological treatments mighthave the potential to deliver acceptable, effective, and safe 
treatment options more quickly3. Building bridges between psychological treatment and other 
modalities such as via combination approaches could also benefit many. But it will not be 
easy. New trials of psychological treatments are greeted not only with enthusiasm, but also 
controversy. Questions are constantly being raised about trial design, implementation, and 
interpretation. Do trial populations reflect real clinical populations? What is an appropriate 
control group? At what point should trial evidence be translated into day-to-day practice? 
How can an intervention be disseminated nationally and internationally? Current assumptions 
are also being queried. Is single-session therapy feasible? Is one, consistent therapist an 
optimal or even necessary component of psychological treatment? How can new technologies 
best be harnessed?  
In the following sections, we use the term ‘mental disorder’. We note that in the wider 
literature many terms are used including mental health disorder, psychological disorder, 
psychiatric disorder, mental health problem, as well as other forms of psychological 
treatments terminology such as mental health difficulties, behavioural difficulties and so 
forth. For consistency the term mental disorder is used in the current commission.  
 
A core role for psychological treatments in the future requires a research agenda 
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The burden of mental disorders is enormous, and yet current pharmacological and 
psychological treatments offer only limited effects for reducing disease burden. Since the 
majority of patients prefer psychological treatments over pharmacological treatments4, 
increased research efforts are required to evolve psychological treatments to the level of 
significant impact upon mental disease burden worldwide. But in order to realize the 
development of psychological treatments, a research agenda is needed that can guide this 
field for the coming years. For example, a 2014 commentary on improving psychology 
treatments stated “By the end of 2015, representatives of the leading clinical and 
neuroscience bodies should meet to hammer out the ten most pressing research questions for 
psychological treatments. This list should be disseminated to granting agencies, scientists, 
clinicians and the public internationally…reconsider the proportion of investments in mental 
health relative to other diseases”2.   
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Mental health disorders are widespread and costly 
Every year almost one in five people worldwide suffer from a mental disorder6, and more 
than 750,000 people die by suicide7. In 2010, mental and substance use disorders accounted 
Panel 1. Methodology and approach used in preparing this Commission 
This commission arose from an initial consultation meeting in December, 
2015, in which researchers from a variety of backgrounds with interests or expertise in 
psychological treatments research met to discuss challenges in the field, and to lay out 
possibilities for a future research agenda for advancing the science of psychological 
treatments. The group’s common interest was captured by Kazdin’s call to arms to 
“reboot psychotherapy research and practice to reduce the burden of mental illness”5.  
Attendees’ backgrounds in terms of subject disciplines included clinical psychology, 
psychiatry, neuroscience, experimental psychology and pharmacology. The language 
of the meeting was English, and attendees were from the UK, Europe and USA. We 
have cited only papers that have been published in English. The commission 
expresses the authors’ collective views about some of the key areas in which we see 
scope for improvements in the field. It was not our goal to provide an exhaustive 
literature review, nor a systematic review of specific topics. Rather, we have cited 
sources that are relevant to the issues that we have discussed in the context of each of 
the ten themes. We note that there continue to be many more important topic areas 
and perspectives, and that this is a start for necessary and continued discussion. 
 
The commission is comprised of ten parts, each of which contains a theme that we 
consider critical to the development and improvement of research on psychological 
treatments: mechanisms of psychological treatments, deployment of psychological 
treatments, cross-modal treatment approaches, prevention and early intervention, the 
role of technology in psychological treatments, evaluating psychological treatments, 
interdisciplinary training, complexity of mental health problems, suicidal behaviour, 
and finally, future directions in the development and innovation of psychological 
treatments. 
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for 183.9 million disability-adjusted life years (DALYs,8) , with most disease burden caused 
by depressive disorders, anxiety disorders and substance-use disorders. The tremendous 
impact of these disorders is ongoing397. These numbers are likely to be underestimates given 
that it is assumed in these calculations that mental disorders are not associated with excess 
mortality, except suicide. There is increasing evidence, however, that people with a mental 
disorder have a considerably higher risk of dying earlier than those without mental disorders9.  
 Apart from the personal suffering of affected patients and their families, mental 
disorders pose enormous economic challenges to communities and societies in terms of 
production losses and health and social care expenditures10-12. The global cost of mental 
health conditions in 2010 has been estimated at US$ 2.5 trillion, and these costs are expected 
to grow to US$ 6.0 trillion by 203013. It is for this reason that conceptualizations of mental 
health need to expand beyond the notions of disease or infirmity to functionally related 
outcomes, or more broadly speaking, the ability to adapt and to self-manage14. 
Current treatments make as yet a limited contribution to the reduction of the disease 
burden 
Several evidence-based biological and psychological treatments are available for a range of 
mental health disorders, however,  these are estimated to be able to reduce the disease burden 
by only approximately 40% and that is only under optimal conditions, when all patients with 
a mental illness receive an evidence-based treatment15. Coverage (i.e., the proportion of 
people who receive a consultation for a mental disorder) is typically much lower than 100%, 
is hardly above 50% for any disorder in any country, and for some disorders (e.g., alcohol-
related disorders) is below 10%398.According to the 2014 Adult Psychiatric Morbidity 
Survey, there has been a welcome increase in people with common mental health disorders 
receiving treatment, largely attributed to the use of psychotropic medication16. Unfortunately, 
the majority of patients treated for mental health disorders do not receive evidence-based 
treatments but rather receive a wide array of treatments including interventions with no 
evidence-base17.  
Patient preference for psychological treatment options alongside restricted availability 
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In the USA, psychotherapy has assumed a less prominent role in mental health care20. For 
example, in the USA the use of antidepressants almost doubled between 1996 and 200518, 
(from 13 to 27 million individuals), whereas among antidepressant users the percentage of 
people who underwent psychotherapy declined from 31.50% to 19.87%.18  From 1999 to 
2010, on average 8.6% of adult depression visits included the prescription of a Second-
Generation Antipsychotic19 – this rate doubled during this period from 4.6% to 12.5%. By 
contrast, there are indications that the majority of patients prefer psychotherapy over 
medication: a meta-analysis of patients with a range of mental disorders (including 
depression, anxiety, insomnia, bipolar disorder, schizophrenia, substance-related disorder, 
eating disorder, and personality disorder) estimated that approximately 75% of patients prefer 
psychotherapy as their treatment4. Meanwhile, clearly some patients prefer pharmacological 
treatment, and some might have no preference. We do not seek to reinforce what we believe 
to be a misplaced dichotomy between biological and psychological approaches (see Part 3, 
on Combination Treatments). Rather, we seek a research agenda that is open to multiple 
perspectives, does not neglect one at the expense of another, considers links, is informed by 
patient preferences, and ultimately leads to the greatest clinical impact.  
Although the majority of patients prefer psychotherapies to medications, the 
availability of such treatments is a major problem in many if not most countries5, because of 
financial constraints, or because there are not enough trained psychotherapists to deliver the 
evidence-based treatments. This means that psychotherapies are mostly delivered in high-
income countries, to those who can afford it and know the ways to find therapists. In low-
income and middle-income countries, psychological treatments are scarce with notable 
exceptions21 (see also Part 2, Worldwide).  
 Several alternatives are being developed to increase access to psychological services, 
such as the Increasing Access to Psychological Treatment (IAPT) program in the UK, where 
low-intensity psychotherapies are made available on a large scale and high-intensity therapies 
are available for those who do not respond to low-intensity therapies98. Internet-based 
interventions (see Part 5) can help in making psychotherapies available to those who need 
them because they can be offered relatively inexpensively and with a low threshold for 
access. Another important development to make therapies more accessible is to use lay-health 
counsellors (see Part 2, Worldwide). 
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Psychological treatment research in tomorrow’s science 
Improved psychological treatments are needed to help reduce the burden of mental disease 
worldwide. The psychological treatment research landscape is ripe for invigoration – it offers 
truly exciting and opportune areas for mental health sciences. Recruiting insights from 
multiple areas of science might allow us to ‘stand on the shoulders’ (to borrow a well-used 
metaphor from Isaac Newton)395.of existing evidence-based psychological treatments and 
‘see further’ in order to improve psychological interventions. Greater collaborative 
endeavours between clinical and basic researchers of many disciplines will help in this 
regard2. 
Here we discuss opportunities to focus future research efforts to improve mental 
health. Ripe areas of enquiry include understanding the mechanisms that underlie 
psychological treatments, increasing their worldwide access, developing cross-modal 
treatment approaches, and (4) enhancing a preventative focus and developmental approach. 
To do this we need to harness tools provided by new technologies,  improved trials 
methodology, and improved training in interdisciplinary mental health sciences to name but a 
few. The targets of psychological treatments should embrace challenging areas, such as the 
inherent complexities of mental health disorders and of  suicide prevention, as illustrated 
here. We have addressed each of these ten key themes in separate parts of the Commission. 
The array of challenges ahead to which a psychological perspective can contribute will 
require fresh innovation. 
Such research  requires ideas to be tested, rejected, or developed in line with scientific 
method and the mental health challenges of the time (rather than, for example, therapeutic 
habit and allegiance to a way of clinical training, or science focused inwardly on science 
rather than its genuine application). This means that we need change. We therefore make an 
analogy with a British contemporary art initiative – which engages with London’s Trafalgar 
Square’s empty plinth. There are statues on three of four of the plinths in the corners of 
Trafalgar Square. The fourth plinth stood empty for over a century (figure 1). Now, the so 
called “Fourth Plinth Programme”22 invites world class artists to make ‘astonishing’ new 
works for the centre of the capital city. Commissions create a rolling programme of 
temporary artworks rather than settling permanently on one figure or idea. These resultant 
sculptures tend to be shown for a year, sometimes only months – sometimes there are gaps. 
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But the momentum and scrutiny continues. Some art works stand the test of time, some may 
not. Associated initiatives encourage projects and creative thinking around past and present 
artworks displayed on the Fourth Plinth. Meanwhile, the best use of the fourth plinth remains 
the subject of debate and discussion in the public, media and art world.  
Bringing this metaphor back to psychological treatments research, innovation, 
rotation of ideas, and robust critical debate need to be a clear part of the way forward. The 
objects of enquiry might change, but the principles of seeking to improve our research efforts 
towards improved mental health will persist. Rather than being prescriptive regarding the 
future of psychological treatments research, this Commission sets out various suggestions and 
principles to guide the research that should  apply across different mental disorders and 
transdiagnostic processes, approaches, countries and, indeed, to the new and future 
generations of mental health researchers. These principles might change over time and how 
best to strengthen psychological treatments should be subject of research, debate and 
discussion involving both the psychological treatments and mental health science fields, and 
many of those beyond. 
When considering the traditional delivery method of psychological treatments, it is 
fascinating that two humans talking with each other for a matter of hours during therapy 
sessions can bring about changes that remediate years of suffering mental distress. While 
clearly the presence of another human can be helpful, evidence-based psychological 
treatments involve far more than only skills which boost therapeutic alliance. We now know 
therapeutic effects can be achieved without a therapist being physically present (e.g., via 
Internet therapy, see Part 5) and that some psychological techniques can be effective when 
delivered by lay workers with modest training (see part 2). Moreover, neuroscience continues 
to reveal how efficiently the mind can work under various parameters (e.g., in modulating 
memory) by a range of techniques which may or may not require another human to be 
present. The emotional, behavioural and social changes rendered through therapy open 
fascinating mechanistic questions for science, such as, why do effective psychological 
treatments work? The identification of specific targets for mechanistic questions might be 
facilitated not only by quantitative methods but also by qualitative methods, such as detailed 
narratives of individuals’ experiences as they undergo psychological treatments. Once 
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potential targets have been identified in this way, they could be subjected to experimental 
investigation to establish causality for therapeutic change.  
We turn now to focus and elaborate on ten key themes that we see as instrumental to 
consider in developing an agenda to progress the science of mental health treatment research. 
These themes are not exhaustive and many more are to be welcomed for future scrutiny.  
 
 
Part 1: Why do existing treatments work? Making the case for mechanisms of 
psychological treatments 
 
 
Introduction 
It is known that certain psychological treatments are effective but we know little about the 
processes through which therapeutic change occurs. As Alan Kazdin has stated “Although 
there are many EBTs (evidence based therapies) available, there is little understanding of the 
mechanisms of change (i.e., precisely how they work)23. Understanding mechanisms of 
action may be extremely important…”. Knowledge of mechanisms is essential to deriving 
and honing treatment strategies to target agents of change more directly, trim away irrelevant 
strategies, and develop novel approaches that are even more expeditious and effective. 
Knowledge of mechanisms also permits greater precision in matching psychological 
treatments to the needs of each individual to improve outcomes.   
Mechanisms research presents exciting opportunities for psychological treatment 
research. However, most neuroscientific studies in psychopathology have taken simply 
described differences between groups of individuals with and without a diagnosis – an 
approach that cannot identify causal mechanisms. To move the field toward causality, we 
“Although there are many EBTs (evidence based therapies) available, there 
is little understanding of the mechanisms of change (i.e., precisely how they 
work; Kazdin, 2007). Understanding mechanisms of action may be extremely 
important…” 
 
Kazdin, A. E. (2007). Mediators and mechanisms of change in psychotherapy 
research. Annual Review of Clinical Psychology, 3, 1-27. 
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should optimize research on mechanisms by framing it within a clinical treatment context to: 
a) understand how existing treatments work; b) improve these treatments; and c) derive new 
treatments.  
 
What is a mechanism of psychological treatment? 
Mechanisms are “the steps or processes through which therapy (or some independent 
variable) actually unfolds and produces the change. Mechanisms explain how the intervention 
translates into events that lead to the outcome or precisely what was altered that led to 
symptom change”23. A mechanism is an explanatory construct and not simply an intervening 
variable that explains the statistical relation between an intervention and an outcome - i.e., a 
mediator. For example, the finding that changes in perceived self-efficacy and outcome 
expectancy statistically mediate subsequent changes in anxiety and functioning24 does not 
explain how changes in self efficacy and outcome expectancy lead to those outcomes. The 
underlying changes responsible for symptom improvement could involve multiple processes, 
including (but not limited to) neural systems, other physiological systems, cognitions, 
emotions and behaviours. 
 The processes through which psychological treatments produce change often overlap 
with, or complement, mechanisms that are responsible for the onset or particularly the 
maintenance of psychopathology (hereafter referred to as mechanisms of psychopathology). 
The NIMH Research Domain Criteria (RDoC) initiative is directing the search for 
mechanisms of psychopathology away from the constraints of categorical diagnostic criteria 
and towards dimensions of observable behavior and neurobiological measures272. The RDoC 
initiative aims to “elaborate a set of psychological constructs linked to behavioral dimensions 
for which strong evidence exists for circuits to implement these functions, and relate the 
extremes of functioning along these dimensions to specified symptoms (i.e., impairment)”25.  
In essence, the RDoC framework aims to identify biopsychological explanations or “process 
constructs” for clinical phenomena; these same “process constructs” could explain change in 
clinical phenomena throughout treatment. The provisional list of RDoC explanatory 
constructs includes Negative Valence Systems, Positive Valence Systems, Cognitive 
Systems, Systems for Social Processes, and Arousal/Modulatory Systems, with each 
construct comprising more specific subconstructs25. The constructs are assessed with 
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measures that represent at least seven levels (called ‘units of analysis’), including genes, 
molecules, cells, circuits, physiology, behavior, and self-reports. Identifying a mechanism 
using one unit of analysis does not exclude mechanisms identified using other units of 
analysis.  
 
EDITOR PELASE DELETE THIS FIGURE 
Mechanisms of psychopathology vary from being predominantly distal (e.g., effects 
of early life adversity that might have occurred many years previously upon inflammatory 
markers for depression26) to predominantly proximal (e.g., ongoing biases in 
autobiographical memory for depression27) (see28 for a recent discussion of these ideas). They 
also vary from being predominantly fixed (e.g., genes, albeit with variations in expression) to 
predominantly malleable (e.g., negative interpretation bias for ambiguous stimuli).  
Psychological treatments generally target predominantly proximal and malleable mechanisms 
of psychopathology: for example,  attention bias modification training for anxious individuals 
who exhibit selective bias of attention towards threat-relevant stimuli29.  Alternatively, 
psychological treatments may target factors that differ from but compensate for mechanisms 
of psychopathology, for example compensatory cognitive training for psychosis30. Although 
less commonly targeted, distal mechanisms may be particularly important targets of 
prevention efforts. Notably, not all treatment mechanisms are directly tied to mechanisms 
responsible for the onset or maintenance of psychopathology; in some cases, treatments work 
through independent processes, as is the case for applied behavioral analysis techniques for 
treating autism31. 
 
What is the state of the field? 
 
Pivotal evidence-based psychological treatments have evolved by specifically targeting 
identified mechanisms of psychopathology. One example is the treatment of panic 
disorder. Through a series of experimental investigations and animal modelling, 
interoceptive conditioning (i.e., acquired fear of visceral or other internally generated 
stimuli due to pairing with an aversive outcome, as in the case of pairing elevated heart 
rate with the possibility of heart attack) and catastrophic misappraisal (i.e., 
misinterpretations of interoceptive stimuli as harmful or threatening) were recognized as 
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mechanisms underlying the fear of bodily sensations that characterizes panic disorder32-34. 
Psychological treatments were developed to target those mechanisms precisely in the form 
of interoceptive exposure35 (i.e., repeated exposure to interoceptive stimuli in the absence 
of aversive outcomes) and cognitive restructuring36 (i.e., reasoning skills to replace 
catastrophic interpretations with evidence-based interpretations). This type of treatment 
has been shown to be particularly effective for panic disorder, and more effective than 
nontargeted supportive psychotherapy (Hedges g = .35, CI 95% .04-.65)37. Similarly, the 
conceptualization of instrumental reinforcement of compulsions led to a treatment known 
as exposure and response prevention for obsessive compulsive disorder38. In this 
conceptualization, the distress-reducing effects of compulsive washing in response to 
obsessive thoughts of being contaminated reinforce and therefore increase compulsive 
washing with each subsequent obsessive thought; the treatment combines exposure to 
reminders of the obsessive thoughts (such as a dirty piece of clothing) or the thought itself 
(such as the thought of being covered in germs) with prevention of washing. This 
treatment approach is very effective for obsessive compulsive disorder, and more so than 
nontargeted psychological control conditions such as relaxation training (Hedges g = 1.29, 
CI 95%  0.76–1.81)39. Another example is behavioural activation therapy which targets 
deficits in positive reinforcement as a contributing factor for depression40. This approach 
aims to increase access to positively rewarding stimuli and, more recently, achieve actions 
that are value driven and overcome task-related avoidance41. Behavioural activation for 
depression is highly effective relative to comparison control interventions, which included 
waitlist and nontargeted psychological control conditions (Hedges g = 0.87, CI 95% 0.60 
~ 1.15 when collapsed across control conditions)42 [. Overall, this mechanistic approach 
has informed the development of psychological treatments that are more precise, efficient, 
and effective than treatments that do not target specific mechanisms. That said, the 
strongest effect sizes derive from comparisons with no-treatment or wait-list control 
conditions, with the latter potentially inflating effect sizes43, and some of the meta-analytic 
findings presented above included wait-list control conditions (e.g.,42). That comparisons 
to usual-care typically yield lower effect sizes than comparisons to no-treatment or wait-
list controls44 might indicate the importance of common factors (such as goal consensus, 
therapeutic alliance, empathy, expectations and therapist effects) that are relevant to all 
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psychotherapies45. Notably, common factors do not obviate the importance of mechanistic 
research but rather imply the value of taking common factors into account when 
evaluating mechanisms of specifically targeted therapeutic approaches.  
However, despite purported treatment mechanisms, including the ones described 
for panic disorder, obsessive compulsive disorder, and depression, we have little evidence 
for the precise mechanisms through which psychological treatments actually work. 
Although recent developments in neuroscience have ignited more interest, the majority of 
studies to date have not evaluated mechanisms of treatment. Even the study of mediation is 
limited and often hindered by insufficiently rigorous methodology 
23
. For example, while 
there is good evidence for the efficacy of interoceptive exposure and cognitive 
restructuring for panic disorder, and while extinction of fear of interoceptive cues and 
reduction in catastrophic appraisals occur as a result of treatment, we have little direct 
evidence that the treatments work through extinction of conditional fear of interoceptive 
cues or reduction of catastrophic appraisals – a claim that would require that changes in the 
purported mechanisms explain subsequent changes in symptoms. Similarly, while 
behavioural activation for depression might lead to changes in reward processing, there is 
no evidence that the treatment works through changing neural and behavioural sensitivity 
to reward. 
To make matters worse, the focus of psychological research has slowly shifted 
away from a mechanistically informed approach  towards ‘modifying or adapting’ 
existing manualized psychological treatments, sometimes superficially, for different 
populations and settings. This approach of modification most commonly applies to 
cognitive and behavioral therapies. Although valuable for the advancement of treatment 
implementation in different settings, this has resulted in a regrettable divorce from the 
foundations of mechanistically informed psychological treatments that in turn has 
thwarted investigation of their mechanisms of action. 
Why is it important to understand mechanisms of psychological treatments? 
Without knowledge of mechanisms, pathways to intervention development and refinement 
remain limited. With knowledge of how change occurs, therapeutic strategies that more 
directly, precisely and effectively produce such change can be developed46. Also, those 
therapeutic strategies that do not affect the critical processes can be removed, making 
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treatments more efficient as well as more effective46. Moreover, by refuting a purported 
mechanism, research attention can be redirected toward investigating alternative 
mechanisms and to the development of novel treatments that most effectively and 
efficiently target them (panel 1). 
 
 
Panel 2. Reasons for Understanding Mechanisms of Psychological Treatments 
 Hone treatments to target processes responsible for change more directly and 
efficiently 
 Uncover essential moderators of treatments outcome and improve precision in 
treatment matching 
 Develop training programs for prevention of and recovery from psychopathology 
 Eliminate wasteful and inefficient treatments 
 Provide evidence for specificity above and beyond nonspecific factors responsible 
for the “dodo bird” effect 
 
Knowledge of psychological treatment mechanisms might uncover moderators of 
treatment outcome, and thereby lead to greater precision in matching treatments to 
individual needs44.. For example, initial interest in attention bias modification training for 
anxious individuals waned as a result of mixed findings and small effect sizes47. More 
recent research has provided some indication that the effects of attention bias modification 
training are larger for individuals with greater attentional bias at baseline29 and for those 
with low expressing forms of the serotonin transporter gene (5-HTTLPR)48. As another 
example, it has been suggested that extinction-based exposure therapy to trauma cues for 
posttraumatic stress disorder might function in part by enhancing prefrontal cortex (PFC) 
inhibitory regulation over amygdala responding49. Neuroscientists have identified subtypes 
of individuals with posttraumatic stress disorder, with the majority showing amygdala 
hyperactivation and PFC hypoactivation to trauma reminders and a minority (~30%) 
showing the reverse pattern of amygdala hypoactivation and PFC hyperactivation50. If it 
can be established that exposure therapy works at least partially through enhancing PFC 
regulation of the amygdala, then exposure therapy might be more effective for the former 
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set of individuals with posttraumatic stress disorder compared to the latter. These examples 
simply illustrate ways in which the field could progress. Conclusive findings will depend 
upon replication with substantially larger samples. 
Not only is identification of such “mechanistic” moderators valuable for precision 
in treatment matching, but uncovering such moderators in turn improves the elucidation of 
psychological treatment mechanisms46. To follow the prior example, by studying the entire 
sample with posttraumatic stress disorder (those showing amygdala hyperactivation as well 
as those showing amygdala hypoactivation), the extent to which change in amygdala 
activation serves as a treatment mechanism is likely to be nullified. By recognizing 
individual baseline differences, differential mediational pathways could be uncovered for 
different individuals (such as the possibility of amygdala deactivation for those who 
initially present with hyperactivation and vice versa for those who initially present with 
amygdala hypoactivation). These are simply illustrative examples, but a mechanistic 
approach to moderation avoids the trial-and-error default position of assuming that a given 
psychological intervention strategy works through the same mechanisms for everyone. 
Another example of such speculation is the hypothesis that behavioral activation for 
depression41 (which involves scheduling activities that are rewarding) leads to symptom 
improvement through enhancing approach motivation or initial responsiveness to reward 
within ‘Positive Valence Systems’ for some individuals, while for other individuals it may 
reduce threat or potential threat within ‘Negative Valence systems’ or even modulate 
‘Arousal Systems’ through regulating sleep-wake cycles.  
Additionally, psychological treatments with a mechanistic focus can be turned 
into training in every day habits that pertain to prevention of and recovery from mental 
ill health. Such attempts include training in mindfulness techniques to reduce affective 
memory bias and reduce development of, or relapse into, depressive ruminative states51. 
Another example is the delivery of cognitive behavioural therapy (CBT) as an adjunct 
to usual primary care for individuals who are depressed and have not responded well to 
medication alone52. In one study, short-term focused CBT was associated with 
significantly lower scores on depression three to five years later relative to usual care 
alone52. Similarly, cognitive therapy decreased recurrence of depression relative to 
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treatment as usual over a ten-year interval in remitted patients with histories of 
recurrent depression53. Together, these data suggest that CBT/CT provided skills that 
were embedded into everyday lives and led to sustained improvements in the long term. 
 Failure to address mechanisms of psychological treatments bears certain costs. For 
example, the development of novel and more effective treatments could be stymied by 
continued focus of attention upon modifying procedural elements to existing treatments 
without fully understanding the processes that lead to change. We encourage the development 
of a larger evidence-base for critical processes for therapeutic change, and specifically for 
which psychological treatments (existing and newly developed) “hit” which processes. This 
evidence-base can and should include common factors as well as specific factors of 
psychotherapies25. It will be informative to know which psychological treatments exert their 
effects primarily through common, nonspecific factors versus more targeted, specific factors, 
and whether the common and specific factors are of greater relevance for one mental health 
problem or individual over another. Moreover, such an evidence-base offers the potential to 
move the field forward beyond the longstanding debate between (a) all psychological 
treatments are equally effective (i.e., “dodo-bird hypothesis”)54 and (b) differential treatment 
effects55. That is, we have the opportunity to evaluate whether matching mechanistically 
focused treatments to individual profiles of underlying dysregulation leads to superior 
outcomes relative to nonspecific factors that are common across psychological treatments. Of 
course, applying mechanistically focused personalization and understanding the role of 
common factors are not the only pathways by which we can improve psychotherapy 
outcomes; other factors that warrant consideration include the personal resources and social 
context of those in need, as well as the service delivery systems in which treatments are 
delivered.  
 
Panel 3. Recommendations for Identifying Potential Mechanisms of Psychological 
Treatments 
 Develop a model of explanatory specificity 
 Experimental investigation of an explanatory construct to establish causal validity 
o Human studies to demonstrate that manipulation of purported construct 
leads to symptom change (experimental psychopathology) 
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o Animal studies to allow more precision and elucidation of targets that 
cannot be studied in humans 
o Reverse-translation models utilizing clinical research to inform models to be 
tested in animals 
 Iterative reciprocal information flow between experimental psychopathology 
studies in humans and animals 
 
Experimental psychopathology 
As reviewed by Kazdin23, mechanisms involve a deep level of explanatory specificity and 
hence are theory-driven. They are elaborated through plausible and coherent reasoning 
based on integration with broader scientific knowledge, and at the same time possess 
specificity in the explanation provided for how change in the mechanism in turn accounts 
for change in outcomes
23
. Once theoretical mechanisms have been elaborated, they are 
subjected to experimental investigations that validate their causal influences upon selected 
outcomes. This endeavour is represented in the field of “experimental psychopathology” 
(see panel 3). 
Demonstration that experimental manipulation of a purported mechanism leads to 
symptom change is a powerful method for validation. Experimental studies of this kind 
in human samples can identify key processes that maintain or change aspects of 
psychopathology. These studies also elucidate which of the processes underlying 
psychopathology can (versus cannot) be modified, and therefore are appropriate 
treatment targets. A recent burgeoning of interest in the mechanisms that underlie 
psychopathology has been fuelled largely by advances in cognitive science and 
neuroscience46. As one example, increased activation in affective brain networks and 
decreased activation in cognitive control and social cognitive networks as youths listen 
to criticism from their mothers has been identified as a potentially critical mechanism in 
emotional development56. These findings could inform strategies aimed at increasing 
effective parenting to reduce the risk of mental health problems in offspring. 
The direct application of identified mechanisms of psychopathology to mechanisms 
of psychological treatment is well-represented in fear learning and exposure therapies for 
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anxiety disorders. For example, pharmacological agents that facilitate the consolidation of 
fear extinction learning (e.g., d-cycloserine) have been shown to have beneficial effects in 
the context of exposure therapy57 (although there are some mixed effects, possibly due to 
mechanistic moderators58). Another example derives from the evidence that retrieving 
already stored memories induces a process of reconsolidation59. Once retrieved, the 
memory has to be rewritten into long-term memory, which requires neurochemical 
processes (de novo protein synthesis) in the brain. This process give rise to the fascinating 
possibility of changing memories post factum, during the reconsolidation time window 
upon retrieval. Engaging in a highly visually- absorbing computer game (‘Tetris’) after a 
memory-reminder cue was found to interrupt reconsolidation of intrusive visual memories 
induced by experimental trauma63. Pharmacological agents (sch as propranolol) and 
behavioural techniques (extinction) have been shown to interrupt the reconsolidation 
process in humans, albeit with some mixed results60, limiting boundary conditions and 
conceptual challenges62.  
Demonstrations of disturbances in autobiographical memory as potential 
mechanisms of depression have led to novel therapeutic strategies, such as memory 
specificity training or positive memory elaboration for depression27. More mechanistic 
research is needed in general and particularly in young people, where there is great need 
for innovative psychological treatments that precisely target narrowly specified 
mechanisms consistent with developmental models of aetiology (see also Part 4, When in 
life). 
Purported mechanisms can be tested in animals with a much more precise level of 
measurement and causality than is possible in human beings. Animal studies are invaluable 
for identifying basic processes and mechanisms that are not possible to address in humans 
due to practical or ethical constraints. Indeed, the clinical applications of d-cycloserine for 
exposure therapy and the disruption of reconsolidation for fear memories first derived 
from careful experimentation in animals59,64. Animal studies have also elucidated the 
potential value of disruption of reconsolidation in the treatment of substance abuse or 
dependence65. Ongoing animal work is currently examining pharmacological agents that 
regulate the stress response via inhibition of the renin-angiotensin system (i.e., losartan) as 
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another method for enhancing consolidation of extinction66. Advances in understanding the 
neurobiology of rodent self-grooming may identify potential treatment mechanisms for 
repetitive behaviours such as compulsions67.  
In reverse-translation approaches, clinical research informs models to be tested in 
animals. For example, paradigms for assessing depressive cognitive styles such as 
pessimism that have been validated in human samples have now been reverse-translated to 
paradigms that measure judgment bias in rodents68. Similarly, drawing from human work 
on reward systems, paradigms have been developed to assess decision making between 
cues that predict reward versus cues that predict punishment in rodents69. 
In spite of these examples of iterative reciprocal information flow between 
experimental studies in humans and animals, for the most part a huge gap exists between 
basic and clinical researchers, which hinders the development of more refined animal 
models of psychopathology and treatment and their translation to clinical samples. The 
reverse and forward translation of advances in basic science and clinical science is 
essential. 
 
 
Evaluation of mechanisms 
Once a mechanism has been identified through careful experimental demonstration, for 
example via experimental psychopathology studies, then it can be evaluated within the 
context of adequately powered clinical trials. This requires measures of the purported 
mechanisms that are reliable, valid, and sensitive to change, as these measures will 
become the mediators that are evaluated statistically. A major contribution to this effort 
will be funding to establish a list of candidate mechanisms that explain therapeutic change 
(based on demonstrations that their experimental manipulation influences selected 
outcomes in animal or human studies) and a list of measures for each candidate 
mechanism. Here, the RDoC notion of units of analysis provides a helpful framework for 
choosing measures from multiple modalities. 
Kazdin
23 has carefully outlined the steps necessary in order to establish that a 
measure is a mediator of a psychological treatment. As an initial step, a strong association 
must be demonstrated between the psychological treatment and the hypothesized mediator 
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(i.e., the mediator changes over the course of treatment), and between the mediator and 
therapeutic outcome (i.e., change in the mediator is related to clinical outcomes). Kazdin23 
lists several methods that allow greater attribution of causality to the mediator (underlying 
mechanism). One method is temporal precedence, since mediation cannot be presumed 
unless changes in the purported mediators (underlying mechanisms) occur prior to and 
then predict changes in outcomes. Temporal precedence necessitates repeated 
measurement of mediators (underlying mechanisms) and of outcome variables throughout 
treatment, ideally in every treatment session. 
Greater attribution of causality also derives from evidence for specificity of the 
linkages; the finding that multiple mediators explain an outcome is much less convincing 
than identifying a single, targeted mediator. Even more convincing is when the purported 
mediator (underlying mechanism) of a particular psychological treatment predicts 
outcomes relative to an alternative mediator of a different mechanism that is not 
theoretically tied to the treatment. Moreover, stronger mediation by a purported mediator 
for a treatment to which it is theoretically tied relative to a treatment to which it is not 
theoretically relevant is another avenue for demonstrating specificity. Evidence for a dose–
response relationship, in which stronger doses of the proposed mediator are associated with 
greater changes in symptoms, also strengthens the argument for causal linkage. The 
consistency with which the relations are observed, across independent replications, is 
another validator. Although for certain mechanistic questions appropriately powered 
experimental studies of small samples can be informative, the demonstration of these 
criteria will require large samples, so collaborative, multi-site studies will be needed, which 
will require a strong investment from funders and collaboration among researchers, 
focusing on common goals. 
Finally, the field would be advanced by a listing of the various therapeutic 
elements that comprise psychological therapies, as has already been initiated70. 
Psychological treatments are mostly packages of different elements, such as cognitive 
restructuring, self-monitoring, problem solving, relaxation training, or assertiveness 
training. The more elements that are combined in a psychological treatment, the harder it 
is to establish mechanistic specificity. Greater precision is likely from evaluating the 
mechanisms of particular procedural elements rather than combinations of elements71 (see 
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Panel 4). Greater collaboration between clinical researchers and basic scientists combined 
with new methods and technologies position us to make more headway than ever before in 
understanding the mechanisms of change in evidence-based psychological treatments. 
 
 
Panel 4. Recommendations for Evaluation of Mechanisms of Psychological 
Treatments 
 Evaluate within the context of adequately powered clinical trials 
 Develop measures (i.e., of mediators) that are reliable, valid and sensitive to 
change and represent multiple modalities (genes, molecules, cells, circuits, 
physiology, behavior, cognition, self-report) 
 Establish mediation by showing change in mediator over treatment and that change 
in the mediator precedes and predicts clinical outcome 
o Temporal precedence (change in mediator precedes and predicts 
subsequent change in symptoms); value of repeated measurement 
o Specificity of mediation to a single or limited number of mediators 
o Specificity of mediation to a theoretically-relevant mediator versus non- 
relevant mediator for a given treatment, or of a theoretically relevant 
mediator to one treatment relative to another treatment to which it does 
not have theoretically relevance 
o Dose response relationship between degree of change in mediator and 
degree of clinical improvement 
o Consistency in independent replication 
 Evaluate mediation for elements or specific therapeutic strategies rather than 
packages of treatment elements 
 
Part 2 Where can psychological treatments be deployed? Research to improve mental health 
worldwide 
Introduction 
Low or no access to efficacious psychological treatments is not only a major problem for the 
majority of people in low- and middle income (LAMIC) countries, but is also problematic for 
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many people in high-income countries. Brief, flexible, modular and efficacious treatments 
derived from mechanistic research could enable us to adapt such treatments more efficiently 
to different cultural contexts. Furthermore, they could help us train lay persons with no 
previous experience of providing services within mental health to help implement such 
interventions within a frame of low-intensity treatment using modern techniques on a broad 
basis both in LAMI and high-income countries. Further research is needed on 1) how to 
derive such treatments and adapt them to the local needs, priorities, traditions, and cultural 
norms for different environment, 2) education and training for lay persons to acquire 
proficiency to deliver such treatments as lay counsellors in a sustainable way, and 3) models 
of delivery of mental health with long-term sustainability.  
Psychological treatments from an international perspective 
 As discussed, mental disorders constitute a significant part of the overall burden of disease 
worldwide8,73. Mental disorders also interact with other serious health conditions such as 
cardiovascular diseases, ischemic stroke, and HIV, increasing the risk of premature death75,77. 
Efficacious psychological treatments for a wide range of mental disorders have mainly been 
developed in North America or Europe, and are typically designed for delivery through one-
to-one psychotherapy by highly trained professionals. However, at a global level, 90% of 
individuals with mental health problems do not receive treatment78. Low or no access to 
efficacious psychological treatments is not only a major problem for the vast majority of 
people in low- and middle-income countries (LAMICs)79, but is also problematic for a 
significant portion of people in high-income countries80. We will have only limited success in 
decreasing the prevalence and incidence of mental illness without a major shift and expansion 
in clinical practice and intervention research. 5 
Panel 5. What Increases Access to Psychological Treatments Worldwide? 
 Existence of low cost, simple, specific and effective treatmentsTask shifting: 
educating people without prior experience of work within mental health services to 
deliver psychological interventions 
 Low intensity intervention: self-help interventions comprising the most potent 
components of effective psychological treatments that can be provided through 
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books, CD/DVD, Internet or other media combined with brief, usually remote, 
support (e-mail or phone) during a few weeks 
 Cultural adaptation: rooting the treatment in sociocultural context (traditions, 
expectations, norms, symbols, etc.) to make sure that it is perceived as intended 
 
Lack of skilled human resources (i.e., therapists) and low acceptability of 
psychological treatments across cultures have been suggested as the two major barriers for 
increasing access to evidence-based psychological treatments in LAMICs81. WHO estimated 
a shortage of 1.18 million mental health workers for 144 LAMICs82. Other significant 
barriers include prevailing public-health priority agendas and inadequate investment in 
mental health care, stigma associated with accessing mental health care, and challenges in 
using primary-care settings for implementation of mental health care83. 
Research to improve worldwide access to psychological treatments 
Global access to psychological treatments could become a reality given adequate global and 
local political decisions and a research agenda including (and not limited to) the following 
conditions (see also panel 5). Characteristics of psychological treatments would be 
advantageous for the successful scale-up of psychological treatments would be that they are 
brief, flexible, modular and efficacious, streamlined to remove any and all complexities 
unnecessary for treatment gains. Such treatments will be aided by research into mechanisms 
of action in psychological treatments (see Part 1), and a consideration of the core 
psychopathology of, and across, mental disorders. Large and complicated psychological 
treatment packages can be delivered only by highly trained professionals to a minority of 
people who can afford the high costs associated with such treatments. On the other hand, 
simplified, clearly defined treatments may be more readily adapted to local needs and 
delivered by lay mental health workers on a larger scale, and delivered as low-intensity 
treatments e.g., via the Internet. Mechanistically informed treatments could also afford 
flexibility, for example in shaping the treatment in line with local cultural norms and 
conditions. For example, if one of the major maintaining factors in depression concerns lack 
of positive reinforcement in daily life (c.f. Part 1, Mechanisms, Positive Valence Systems), 
then treatment strategies to increase positive reinforcement can be formed in many different 
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ways depending on what is the most relevant, acceptable, and affordable in the specific 
context or culture in which the problem exists, e.g. via various cognitive, behavioural or 
psychosocial techniques. Such treatments could each have flexible forms, but be functionally 
identical. 
Psychological treatment development in LAMICs has typically focussed on 
availability and access, and researchers have taken a pragmatic approach to treatment 
development itself. Future research will harness scientifically driven developments. 
Developing psychological treatments on the basis of sound psychological theories and 
empirical knowledge gained from research on the processes of action in treatment may afford 
particular strengths by opening opportunities for cultural adaptation and psychological 
treatment across international contexts. Research that has tested theories about the 
mechanisms of action of various forms of exposure therapy for anxiety disorders88 has 
provided invaluable knowledge, leading to the enhanced flexibility of exposure therapy, 
which in turn could be tailored for global adaptation. It is the hope that the findings of 
research on basic mechanisms will indicate potential for brief and highly efficacious 
psychological treatments2. Future research needs to move such work into intervention formats 
and modules that are acceptable and efficacious cross-culturally, and are deliverable on a 
wider scale.   
We need to rethink the traditional models of one-to-one delivery of psychological 
treatments by skilled psychotherapists who have had many years of training, and consider 
more efficient ways of treatment delivery5,93. Given the limited human resources in terms of 
highly trained and skilled professionals internationally, a shift towards collaborative models 
of care delivery has been proposed in which novel strategies such as task shifting (e.g., 
educating people with no prior experience of work within mental health services to become 
lay counsellors) has been successfully used to deliver streamlined treatment of psychological 
disorders with promising results81,94-95. Nevertheless, empirical questions remain: how best 
can we train people to become lay counsellors in a sustainable way, and what barriers might 
there be to such sustainability? The delivery of therapy in group rather than one-to-one has 
clear benefits for delivery efficiency since the therapist to patient ratio is decreased. 
Other research questions include how many training, supervision, and booster 
sessions will be needed to ensure high quality delivery of treatments? The majority of studies 
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in which potential treatment group leaders have received brief training (1-4 weeks) have 
shown effective outcomes,97  but more research is needed in this context. While task shifting 
and training the trainer have been pioneering in a global mental health context, these are not 
strategies used in developing countries alone. For example, IAPT 98 resembles an advanced 
form of task shifting (rapidly educating a new category of mental health professionals called 
‘Psychological wellbeing practitioners’), with its strengths and limitations that help us 
improve future large-scale endeavours. How can technologies be employed to train on a large 
scale and to maintain fidelity of treatment delivery? Models of training inexperienced 
clinicians with the aid of computerized guides have been employed in primary care clinics in 
the USA, albeit on a much smaller scale than IAPT100. Research using the outcome and long-
term follow-up data arising from such endeavours will yield many lessons as to how to 
increase access to psychological treatments worldwide. 
Technology is another important pathway by which to open the availability of 
psychological treatments93 (see also Part 5, Technology). The use of the Internet or mobile 
phones to provide psychological treatments combined with minimal individual support 
through e-mail or telephone has shown highly promising results in many studies in high-
income  countries102 but few studies have tested such interventions in LAMICs107 . More 
research is required, particularly as mobile phones are rapidly becoming available worldwide, 
as is the availability of the Internet 108. 
Low-intensity treatments delivered by computerized or mobile-based guided self-
help technologies present an ideal early option in a stepped care model of treatment. National 
guidelines are starting to propose the use of low intensity treatments as a first option to 
improve the availability of efficacious treatments (e.g., for bulimia nervosa and binge eating 
disorder109). Countries such as Sweden and Australia have led the way in research on 
Internet-based treatment and the implementation of low-intensity treatments with examples 
from eating disorders112  to parent training111 - for a meta-analysis for mental and somatic 
disorders, see 110.  Such work provides models and lessons that can be used or developed for 
improving access to care worldwide. For example, the internet may offer enhanced 
possibilities for long-term follow-up after a standard course of psychological treatment has 
ended and the implementation of booster sessions.  
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Contextual factors play an essential role in any efforts to increase access to 
psychological treatments and are in themselves a topic for future implementation research. 
The involvement of all stakeholders is a key factor in scaling up services to ensure support 
and to facilitate sustainability118. Initiatives to improve mental health in LAMICs need to be 
rooted in the local society to assure sustainability, and in order to illuminate ways to 
maximise and achieve this. Engaging the local government, considering local legislations and 
traditions, involving patient organisations, creating conditions for continued education, and 
mutual exchange are important candidates. One area that currently demands research is 
efforts to help people who are refugees from war and persecution119. Not only are treatment 
developments imperative, but particular contextual factors require investigation (e.g., moving 
populations, multiple trauma experiences). 
 The stigma related to mental health problems is another barrier to improved access 
to treatment that requires further research. Understanding and addressing the relationship 
between religious/cultural beliefs and attitudes towards mental health is a crucial factor. The 
potential of media such as radio and TV to combat the stigma related to mental health and 
seeking treatment for mental health problems warrants investigation. As an example, there is 
clearly stigma related to talking openly about family planning among people living in poor 
communities in some LAMIC. The successful use of a well-designed TV-series to improve 
family planning and to reduce fertility rates in Mexico120 is a good example of the effective 
application of such strategies to reduce stigma. . The “Headspace” initiative in Australia 
(https://www.headspace.org.au) provides a model that could be adapted to different cultural 
contexts and norms with the goals of decreasing the stigma of mental illness and facilitating 
access to treatment. 
The economic aspects of international mental health efforts should also be subject to 
more rigorous research. Evidence from the UK121 suggests that the payoff for psychological 
treatment approaches such as early intervention for psychosis, conduct disorder and suicide 
prevention has a ratio higher than 10 (i.e., for every £1 invested in such intervention, there 
will be more than £10 benefit). Future research designs should include cost-effectiveness 
analyses regarding the broader provision of psychological treatments in resource-limited 
settings, both in developed and developing countries.  
 
 
 
32 
 
 
Research collaboration and exchange between cultures 
Focusing on international mental health in order to bring about improvements in 
psychological treatments would best be enabled by a mutual exchange of knowledge, 
experience and expertise between disciplines and across geography (see also Part 7, 
Training). Opportunities for students and professionals (both scientific and clinical) from 
different parts of the world to visit one other to learn about conditions for, and challenges in, 
improving access to psychological treatments in contexts other than their own may prove to 
be a key factor for creating the enthusiasm and lasting collaborations needed to develop 
sustainable interventions. Such an exchange might also facilitate cross-cultural comparisons 
that might contribute to further fundamental understanding and more efficient prevention and 
treatment of mental illness.    
Panel 6. Example Directions for Future Research to Improve Access to Psychological 
Treatments Worldwide 
 Build brief, flexible, modular and efficacious treatments which are streamlined 
based on knowledge from research on mechanisms of action in psychological 
treatments 
 Use the knowledge regarding mechanisms of action of psychological treatments to 
derive treatments aligned with the local needs, priorities, traditions, and cultural 
factors specific to the environment in which the treatment will be delivered 
 Investigate how much education and training is needed for persons without or with 
limited previous experience of work within mental health to acquire proficiency to 
deliver basic psychological treatments as lay counsellors in a sustainable way 
 Investigate how new models of delivery of psychological treatments can be scaled 
up in a sustainable way since the long-term sustainability of most models is unclear 
 Investigate the use of media such as TV, Radio, and Internet to combat the stigma 
related to mental illness 
 
There is a need to continue to work towards increasing global access to psychological 
treatments – both for individuals in LAMICs, but also those in high income nations. Research 
on psychological treatments will position us to continue to develop and evaluate the efficacy 
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of brief, flexible interventions which could be focussed on precise mechanisms of action that 
in turn can be adapted to meet the needs of individuals in different cultural contexts. Training 
lay people to deliver such interventions and scaling treatments for delivery in a manner that is 
sustainable in the long-term are two key directions for future work. 
Part 3 With what? The potential for synergistic treatment effects: using and developing 
cross-modal treatment approaches 
 
Introduction 
Both pharmacological and psychological interventions are commonly recommended as first 
line treatments in psychiatry and the potential for enhancing treatment action through 
combination approaches has started to attract research interest. However, the optimal method 
for treatment combination is far from clear and requires dedicated research in preclinical, 
experimental medicine models and randomised controlled trials. We advocate that such an 
approach should consider the potential for synergy between key mechanisms of action across 
different treatment modalities and consider these treatments within the same research 
framework.  The potential for negative effects of treatment combinations should also be a 
priority for investigation in future research programmes. 
 
Creating synergy and avoiding harm with combination treatments 
An individual with a mental health disorder(s) is likely to receive a combination of different 
treatment approaches as part of his or her care, often including psychological therapies, as 
well as different types of medication and social interventions (panel 7). However, current 
clinical guidelines include little about combination treatments and  the vast majority of 
research focuses on a single treatment at a time, often with the presence of another treatment 
as an exclusion criterion to participation in randomised controlled trials (although see also 
meta-analyses of existing combination treatment studies)124-125. The generalisation of research 
based on single treatments to the typical clinical reality of combination in practice lacks 
validity. Exciting basic and clinical science questions arise about what does happen when 
psychological treatment is combined with other therapeutic approaches. 
Empirical studies suggest that there might be small benefits, for example, when a 
psychological treatment (such as CBT) and a pharmacological treatment (such as a selective 
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serotonin reuptake inhibitor, SSRI) are combined in the acute treatment of emotional 
disorders including depression126. However, the longevity of effects after treatment 
discontinuation may actually be reduced in some cases. For example, in the treatment of 
anxiety disorders, posttreatment relapse has been reported to be higher in patients who also 
received benzodiazepine or antidepressant treatment during CBT than in those who received 
CBT alone or in combination with a placebo127,128. Such findings emphasise the importance 
of capturing clinical effects after treatment end as well as during acute response, and also of 
focusing on potential mechanisms which could underlie these differential outcomes (see 
synergistic vs harmful combination effects panel 7). 
For the most part, combination treatments in the clinic are driven pragmatically; for 
example, a client may receive two effective treatments, often with each from a different 
practitioner (e.g., a clinical psychologist and a psychiatrist). Such an approach contrasts with 
the attempt to combine treatments based on a mechanistic understanding or model. The hope 
is that scientifically informed combination treatments have the potential to create synergy and 
to support a better therapeutic response than either offered alone. Such approaches may be 
used to potentiate the mechanisms that are theorised to support a therapeutic effect or to 
overcome the limitations or barriers to a particular mechanism applied on its own (see Part 1, 
Mechanisms). Interventions that are delivered together with psychological treatments may 
cover multiple modalities and may include the addition of pharmacological agents, 
neuromodulation, social, nutritional, or other forms of psychological intervention such as 
computerised training (e.g., cognitive bias modification, CBM). 
 
Panel 7. What is a Combination Treatment? 
 Combination treatment: the application of two or more types of intervention in 
patient groups, which have been specifically assessed for efficacy in combination. 
In the current context, we refer to the combination of psychological treatments with 
other types of interventions, across modalities, including the addition of 
pharmacological agents, neuromodulation, social, nutritional, or other forms of 
psychological intervention such as computerised training 
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 Synergistic versus harmful combination treatments: some treatments may work 
well together and have greater efficacy than either applied on its own. For example, 
the use of a pharmacological agent to improve learning has been hypothesised to 
enhance the retention of CBT’s benefits58, although see129. By contrast, some 
treatments may impair efficacy in combination.  For example, patients who receive 
benzodiazepines during psychological treatment may show reduced longer term 
benefits of CBT after drug discontinuation128 
 Patient perspective: the views, acceptance and opinions of the individual receiving 
the treatment can influence its effects. Patient preference needs to be considered in 
formal research programs that attempt to bridge the psychological-pharmacological 
divide 
 Pre-clinical: research using animal or human models is needed to understand key 
mechanisms and the effects of novel interventions before translation to clinical 
research programmes. 
 Back translation: The success of translational research depends in large part on the 
validity of the experimental model used to mimic the disorder in the laboratory 
 Back translation is used to describe the use of evidence from clinical research and 
experience to drive, test and refine the development and validation of animal and 
human preclinical models 
 Experimental medicine / experimental psychopathology: the use of a model, 
typically in humans, to explore key mechanisms and processes that are 
hypothesised to be important for treatment action in psychiatry. These models can 
be used to screen novel treatments and to refine their application prior to full 
clinical testing 
 
Utilising contemporary cognitive neuroscience research to boost psychological 
interventions 
Research focused on boosting the effects and retention of psychological treatments has 
utilised recent developments in neuroscience and experimental psychology88. Understanding 
the molecular basis of memory processes provides targets that might be manipulated to 
facilitate extinction, reconsolidation of memories, and learning, which are key components of 
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many psychological treatments, and operate across a number of disorders59,130. Drug 
treatments that facilitate extinction of fear associations, reduce reconsolidation of 
troublesome aversive memories, or enhance retention of more positive memories or 
experiences during therapy might be useful in combination with psychological treatments. 
Augmentation of existing psychological treatments. There has been growing interest in 
the use of drugs targeting the glutamatergic system (such as d-cycloserine) to facilitate 
underlying processes of extinction and retention during exposure therapy in anxiety disorders 
such as agoraphobia, social anxiety and post-traumatic stress disorder58. However, identifying 
the factors which may moderate this benefit is challenging, and a recent Cochrane review 
found no evidence that d-cycloserine vs placebo conferred any advantage overall when 
combined with CBT in the treatment of anxiety disorders129. Direct brain stimulation 
techniques such as Transcranial Magnetic Stimulation (TMS) applied over the medial 
prefrontal cortex (implicated in extinction and inhibition) has been reported to modulate 
conditioned fear learning and extinction in healthy volunteer s131. It is hoped that the use of 
add-on treatments with effects on underlying mechanisms of learning and memory might 
speed up treatment effects, reduce the number of treatment sessions needed, or even help the 
longevity of effects. However, the field requires understanding the best methods to facilitate 
learning in an area where much is still unknown. For example, the optimal parameters for 
supporting learning pharmacologically or through neuromodulatory devices are elusive and 
require dedicated strategic focus to support preclinical work in humans and animal models58 
(see also Part 1, Mechanisms). 
A focus on mechanistically derived combinations also requires understanding and 
predicting the effects of a psychological treatment alone and in combination. For example, 
enhancing learning by pharmacological means (i.e., DCS) in an exposure treatment which has 
failed or where extinction has not occurred would be expected to have counterproductive 
effects; i.e., to strengthen poor outcomes. These complexities underscore the necessity and 
potential impact of elucidating the mechanisms of treatments in isolation and in combination 
(see Part 1, Mechanisms). 
 
The need for better pre-clinical models 
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These observations highlight the critical role for preclinical and experimental medicine 
models in understanding both the key processes and mechanisms that are important for 
treatment combinations and assessing early signals of efficacy for future clinical testing. 
Animal models are commonly used in the pharmaceutical industry to screen novel agents, but 
rarely use a combination approach - i.e., by testing the effect of a drug together with a 
psychological intervention. This may lead to the early rejection of a drug which may have 
weak effects on its own but which may be useful clinically in an adjunctive role with 
psychological treatments. We need strategic focus and funding avenues for mechanistically 
informed treatment combination approaches in animal and in human models. We need to 
enhance the back translation of findings from the clinic to these models and stimulate interest 
in using combination models to assess novel treatments including drug development within 
pharmaceutical industry. Research in this area needs to incorporate measures which can 
assess and predict when and for whom combination treatment will be helpful. Regulatory 
support for this approach (from the FDA and EMA), linked to approval and licensing of 
agents, will be required to allow pharmaceutical companies to develop and test these kinds of 
combined treatments both to facilitate potentially beneficial combinations and to reduce 
potentially harmful ones. 
 
Unifying approaches and measures across treatment research 
Treatment combination across modalities can be limited by the barriers between researchers, 
clinicians and funders operating within these treatment approaches. The framework, 
language, and level of analysis are often different, making it difficult to see natural synergy. 
However, exploring treatments using a common framework may help to reduce these barriers 
and lead to novel hypotheses unpredicted by either approach alone.  For example, recent 
studies have used measures across fields to understand treatment effects, such as using 
neuroimaging to understand and predict therapeutic response to psychological treatments132 
and employing psychological outcome measures to explore the effects of drug treatment133. 
As an example, the focus on antidepressant drug action has traditionally been 
considered at a molecular, cellular or chemical level, but there is increasing evidence that 
antidepressants affect core psychological processes that are important in depression before 
therapeutic effects are observed, and which may help explain their later clinical actions in 
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depression (see133, figure 2). Antidepressants increase the relative processing of positive vs 
negative information early in treatment which may be important in the recovery process from 
depression as the patient experiences more positive feedback and reinforcement, countering 
the negative biases that are theorised to play a key role in maintenance of the disorder134,135. 
A key barrier to the successful translation of these effects into clinical benefit is the 
need for interactions with the environment. If a patient is socially isolated or in a particularly 
toxic environment, then increased positive bias and processing would be expected to have 
only limited effects. Shiroma et al.136 reported that increased positive bias induced with 
antidepressant drug treatment interacted with interpersonal support in the patients’ 
environment to predict therapeutic response (figure 3). This kind of inter-disciplinary 
approach has the potential to generate new hypotheses concerning combination treatment 
which would not have been predicted from either approach alone. Using this example, it is 
predicted that combining antidepressant drug treatment in its early phases with a 
psychological intervention134 which has the potential to increase interaction with the 
environment (such as behavioural activation), may remove a barrier to successful 
antidepressant drug treatment (figure 2). 
To facilitate interdisciplinary combination approaches, increased communication and 
translation are key. Greater collaboration and joint meetings, the use of similar assessments 
and measures, and joint funding initiatives will help support this aim for improved 
combination treatments of the future. This requires organisations, funding bodies and 
researchers to work together, but the results will no doubt be exciting. An example of this 
followed the joint symposium recently presented at two very different meetings (the British 
Association for Psychopharmacology (BAP) and the British Association for Behavioural and 
Cognitive Psychotherapies (BABCP). This symposium, supported by the charity MQ: 
Transforming Mental Health, focused on the divide between psychological and biological 
treatment development and stimulated approaches to start to bridge the gap and align research 
strategy137. We need to build on this exciting initiative, call researchers across fields and set 
strategic funding to strengthen this early promise. 
 
Testing the efficacy of combination treatments 
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Developing and assessing the efficacy of combination treatment also raises complexities for 
trial design and methodology (see also Part 6, Trials). Treatment trials that compare active vs 
control treatment often require large sample sizes to have sufficient statistical power to 
isolate true effects from demand or placebo effects. Exploring interaction effects in 
comparison with individual treatments can require even larger sample sizes, depending upon 
study design. In particular, the effects of two treatments will often be assessed in isolation, in 
addition to their combination leading to a factorial design with 4 groups (treatment 1 + 
placebo vs treatment 2 + placebo vs treatment 1 + treatment 2; placebo + placebo). 
Mechanism studies in particular also need to consider possible state dependency of learning; 
i.e., that memory will be enhanced if tested in the same vs different state, including internal 
states produced by a drug138. This field of combination treatments will therefore benefit from 
a variety of approaches and from testing effects at different time points and under multiple 
conditions.   
Experimental medicine can be used to test hypotheses in smaller controlled studies 
and using surrogate markers of treatment success. This approach has revealed key effects of 
both pharmacological139 and psychological140 treatments used in anxiety disorders on the 
same underlying cognitive processes. This approach has been used to explore the effects of 
combined treatment. For example, the effects of pairing computerised cognitive bias 
modification training with brain stimulation of the dorsolateral prefrontal cortex was assessed 
using reactivity to a stressor as a proxy marker of efficacy in healthy volunteers141. The 
effects of cognitive bias modification and SSRI treatment alone and in combination have 
been explored using the same outcome measure along with effects on negative memory bias, 
showing surprisingly that the combined effects could be worse than either applied in isolation 
in healthy volunteers142. Early changes in these measures are associated with later therapeutic 
benefit in patient groups136 and can therefore be used to guide initial proof of principle 
studies for treatment combination and to reject those which have little therapeutic promise. 
Combinations which appear successful using these surrogate markers can be put forward for 
the next stage of clinical assessment, typically in a randomised controlled trial, with sufficient 
statistical power, and appropriate control conditions. This approach might be supported by 
big data approaches in which the data are collected under more naturalistic conditions (such 
as large scale analysis of medical records or prescribing patterns see Figure ?). Promising  
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treatment combinations and timing of treatment combinations might be isolated by pattern 
analysis from large data sets. To facilitate this, it is important to standardise assessments and 
the treatment elements (see also Part 8 and Panel 18). The triangulation of experimental 
medicine, randomised controlled trials, and big data analysis will be necessary to develop, 
assess, and understand combination approaches of the future. 
 
Breaking down barriers: Psychological and biological treatments can tap into the same 
core processes 
Finally and importantly, patient preference should be considered when evaluating the effects 
of combination treatment. Individuals often express a preference for either psychological or 
pharmacological treatment, so the combination might be a difficult choice for some. This 
division underscores the view mirrored across society, clinical practice, and science that these 
are different processes and approaches; i.e., that there is a dichotomy between a 
psychological or biological view of mental health disorders. This view is challenged by 
evidence that psychological and biological treatments tap into the same core processes and 
represent different methods rather than different concepts133. Challenging these assumptions 
and creating more synergy at multiple levels (including the public, clinicians and scientists) 
will be a critical step towards optimal development of treatments. The ethical implications of 
combination treatments and their development should be incorporated along with these areas 
for research strategy. Finally, we need to consider the attribution of treatment effects from the 
patient’s perspective. For example, if any benefits from combined treatments are attributed to 
the medication, then the long term advantage of CBT can be lessened143. Studies to 
characterise attribution bias in combined treatment approaches and consideration of the 
strategies which may be effective in reducing these effects is a key priority for future work 
(panel 8).   
 
Panel 8. Example directions for Future Research in Combination Treatment 
Approaches 
 Development and validation of preclinical animal and human models for proof of 
principle studies and mechanistic focus in combination treatment research 
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 Elucidating the optimal parameters for enhanced learning with drug treatment 
approaches and the consideration of individual differences in this response  
 Stimulating pharmaceutical companies to develop and assess novel therapeutics in a 
combination role with psychological interventions. Fostering understanding of this 
approach within the regulatory community. 
 Clinical studies informed by proof of principle work to test the efficacy of 
treatments alone and in combination across disorders 
 Consideration of the potential harmful effects of combination treatment for 
treatments which work well in isolation including a focus on attribution bias and 
long term outcome. 
 Research on the views and acceptability of combined treatments in psychological 
disorders and the importance of patient preference and views about treatment for 
their clinical actions. 
 
Figure 2: Antidepressant drugs are hypothesised to work via early changes in negative 
affective bias, i.e., by reducing the influence of this key maintaining factor in depression133. 
This raises the possibility that psychological treatments could be used in combination to a.) 
boost effects of antidepressants on negative affective bias and b.) facilitate the translation of 
effects on bias into clinical action, via increased interaction and exposure to social and 
emotional cues.  
 
In sum, research to date that has tested the efficacy of combination treatments has shown 
great promise for the clinical utility of combining psychological and pharmacological 
approaches. However, there remain many unanswered questions regarding the optimal 
method for treatment combination that need to be addressed in preclinical, experimental 
medicine models and randomised controlled trials.  
 
Part 4 When in life?  Psychological science, prevention and early intervention: getting it 
right from the start 
 
Introduction 
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Opportunities for prevention and early intervention for mental health problems exist across 
the lifespan. However, the early years of life represent perhaps the greatest opportunity to set 
a path to good mental health. This requires both population-based change and the accurate 
identification of those at risk – in both approaches there is need for effective and safe 
interventions. Currently many widely used approaches have limited or no scientific 
underpinning. The rigorous and sustained application of psychological science approaches to 
this area of practice is critical and offers enormous promise. The focus of this section is 
primarily on children and young people.  
 
Prevention and early intervention 
Prevention of mental disorders is one of the main challenges for the future of mental health 
care, because of the high burden of disease of mental disorders for individual and societies, 
the relatively small effect of current treatments and because of the enormous societal costs of 
mental disorders once they have emerged168 The imperative to reduce risk factors across the 
population, and to intervene at the earliest point when symptoms, or precursors, of mental 
distress occur makes human, societal and economic sense144,145. Psychological science can 
inform and underpin the development of these early preventative interventions, even where 
the risk factors are social in origin. 
The early years of life, from conception, through to childhood and adolescence 
represent a wonderful opportunity to set a path to good mental health. Most psychopathology 
has its origin or onset before the age of 18 years147. There is enormous potential to either 
prevent mental health problems or to intervene early to reduce the impact of any mental 
health problems that do occur. The greater plasticity of the brain during childhood, and the 
nature of the emotional and behavioural responses of a child, mean that the potential to 
intervene successfully and powerfully may be greater than at any other point in life. At the 
present time, there is a potentially greater role in early life for psychological approaches than 
for pharmacological and other physical interventions, although many interventions, such as 
nutritional approaches, remain under-researched. For psychological interventions to make 
significant inroads into the effective prevention of mental illness, some key requirements and 
scientific and clinical challenges have to be met2.  
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Panel 9. Psychological Treatments: What are Preventive and Early Interventions? 
Prevention: often defined as those interventions which are conducted before people 
meet formal criteria for a disorder148. Three types are described: universal prevention, 
which is aimed at the general population or parts of the general population, regardless 
of whether they have a higher than average risk of developing a disorder (e.g., school 
programmes or mass media campaigns); selective prevention which is aimed at high-
risk groups, who have not yet developed a mental disorder (an example would be the 
Nurse Family Partnership programme developed in the US which initially aimed to 
prevent later psychosocial adverse outcomes for women and their children in socio-
economically deprived areas149; and indicated prevention which is aimed at individuals 
who have some symptoms of a mental disorder but do not meet diagnostic criteria (an 
example would be the intervention developed by Rapee and colleagues for parents of 
pre-school children who are at risk of anxiety disorders, which has potential long-term 
effects from a brief intervention150. 
 
Requirements and challenges for prevention and early intervention 
Preventive approaches in childhood and adolescence (panel 9) require the identification of 
risk factors or at-risk groups (unless an intervention is going to be delivered to the whole 
population).144 Key early-life risk factors include exposure to severe adversities such as child 
maltreatment, disturbed parenting, parental substance misuse, exposure to domestic and other 
violence, and loss events, such as serious illness in, or death of, a parent151. However, 
knowledge to date is by no means complete, and further research is needed on these and 
additional risk factors, as well as interactive effect between risk factors. 
Identifying and elucidating these risk factors is not sufficient. For change to occur 
there have to be effective and acceptable interventions. These may target modifiable risk 
factors, or may use other theoretical approaches to change, including tackling key 
psychological mechanisms. However,  many early interventions do not have sufficient 
evidence to be considered to be effective. Developing and testing early interventions that 
might reduce risk of psychological illness is a fundamental and largely unmet challenge. 
 
Current research limitations regarding early interventions 
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It is often implicitly assumed that any kind of early intervention is better than nothing but this 
is not the case: almost any intervention that can actually do or change something has the 
potential for harm if used in the wrong circumstances; for example, as has been discussed in 
the area of eating disorders152. The possibility for harm is often overlooked and is probably 
one of the key blind spots in the field of prevention of psychological problems, particularly 
when translated into policy. It is critical to acknowledge that not all interventions are the 
same: even interventions with overlapping appearance or content can have different 
effects153.  
There is a relative paucity of evidence for psychological treatments in many areas of 
child and adolescent mental health practice, particularly for very young children, presenting a 
great opportunity for future research. This is a promising area as where sufficient high-quality 
evidence does exist, differences in treatment effectiveness are emerging55,154. A related 
consideration is that an intervention may not have the same treatment effect in every setting 
or with all individuals equally (see for example apparently contradictory findings for the 
Family Nurse Partnership intervention156). Disentangling these challenging problems is made 
more difficult when the components of a psychological intervention are not clearly specified 
or publically available, perhaps for commercial or some other protective reason.  
A further challenge is a lack of understanding of the mechanisms by which 
intervention occurs in many preventive and early interventions. As set out in Part 1 
(Mechanisms), this is crucial to development of new and more effective methods of 
successful treatment. However, in a preventive and developmental context, this is likely to 
more fluid than at other points in life. For example, different mechanisms may operate at 
different points in childhood, and each of these may be different from the mechanisms 
operating in adulthood, even for the same condition or presenting problem (see also Part 8 
Complexities). There are relatively few well-studied examples of this, although some are 
emerging. For example, research has found that there is no significant evidence that young 
children at risk of anxiety disorders possess the specific cognitive biases for emotional 
stimuli157, where such biases have been identified in adults with anxiety. In early childhood 
there will also be a need to go beyond the individualised mechanisms suggested in the RDoC 
explanatory constructs (see Part 1, Mechanisms). For example, other mechanisms, existing in 
the social world of young children, might open critical pathways to help change precursors of 
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psychopathology, such as via the early relationships, or attachments, that children form to 
their parents or carers. Parental sensitivity has been shown to be a key mechanism of change 
,for example in the context of attachment159, although the detailed processes which might 
then lead to the development of psychopathology remain to be elucidated. A better 
understanding of mechanisms underlying treatment gains will also be critical for any step-
change in effectiveness of prevention and early intervention.  
 
Making interventions stick - persistence of effects 
Another challenge for preventive and early intervention approaches, which is shared with 
many other forms of psychological intervention, is how to make interventions “stick” - not 
only how to make the effects of psychological treatment last beyond the end of the treatment, 
but also how to make them generalise to other areas of life functioning. Relatively few 
psychological interventions have convincing evidence of sustained benefit. We need 
developments in psychological science to inform how to take psychological interventions 
outside of the therapy room, which may make interventions more widely available and 
acceptable, and make effects more likely to generalise to everyday life functioning. The use 
of technologies may aid in this regard (see Part 5, Technologies). One example, which a 
number of research groups are tackling, is how to prevent or treat early signs of depression 
using gaming and other technologies161. A further approach is to take interventions into 
schools162. Both of these types of approaches have utilised primarily cognitive behavioural 
interventions to date, although others, such as Interpersonal Therapy (IPT) also show promise 
for depression in children and young people.     
 
Positive examples for the future 
Three groups of interventions illustrate that preventive intervention and early intervention are 
possible from very early in life, and that longer-lasting benefits are possible (panel 10). All 
three interventions are derived from scientifically rigorous, sustained approaches to 
intervention development, informed by theory. They also highlight some of the challenges 
mentioned above, including that we still have relatively limited understanding of which sub-
groups are most likely to benefit from which interventions. Other preventive or early 
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interventions do exist, with varying levels of research evidence to support them in a range of 
psychological or psychiatric conditions.  
 
Panel 10. Examples of Promising Preventive and Early Intervention Approaches 
Example 1: During infancy, brief, focussed interventions such as ViPP (Video 
Feedback to Promote Positive Parenting: for example, see164) can improve parental 
sensitivity and the child’s attachment relationship with their primary caregiving parent. 
This draws on both attachment theory and social learning theory. There is some, although 
limited, evidence of effects on child behaviour as well for this intervention, which is 
largely lacking for other video feedback parent-focussed approaches at the present time. 
Example 2: In slightly older pre-school children (aged 3-5 years), an intervention for 
the parents of children with increased risk of anxiety disorders (identified by having high 
levels of behavioural inhibition) has been shown to reduce the risk of subsequent anxiety 
disorders.  This intervention was brief (6 sessions), and used an educational approach with 
some behavioural components focussed on exposure. Effects were still seen 11 years later, 
although only convincingly in girls, and shown to be cost-effective using Australian 
criteria for cost-effectiveness150. 
Example 3: In school age children there is consistent evidence of benefit of parenting 
groups based on social learning theory, such as the ‘Parenting Programmes’ to improve 
child behaviour166. Longer-lasting benefits have been demonstrated, and economic 
modelling studies point to societal, financial and individual health gain167. 
 
 
 
Prevention of mental disorders in adults 
In the past two decades, randomized controlled trials have shown that it is possible to prevent 
or at least delay the onset of mental disorders in adolescents and young adults, especially 
depression and psychotic disorders. Psychosocial preventive interventions, typically based on 
psychological treatments such as CBT or interpersonal psychotherapy (IPT), have been tested 
in at-risk populations and in people with subthreshold symptoms of depression or psychosis, 
who do not meet diagnostic criteria for a full-blown mental disorder. Meta-analyses confirm  
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these interventions effectively reduce the incidence of new cases of depressive disorders by 
about 20 to 25%169,170, and prevent or delay the onset of about 50% of psychotic disorders in 
those at high risk for developing a psychotic disorder (171, see also the influential work in 
Australia published by McGorry and colleagues, e.g.172). Preventing the onset of mental 
disorders is one of the most promising areas in which research on psychological interventions 
can help to reduce the disease burden of mental disorders. 
 
The challenges ahead 
Clearly, more research is essential to expand our repertoire of approaches and the range of 
mental health disorders that can be addressed. This includes early preventive approaches 
focussed on infancy and childhood, and interventions through adolescence, when young 
people begin to present with many of the common mental health problems that will affect 
them through adult life. These approaches need to be theory-driven and rigorously trialled 
(see Part 1 Mechanisms and Part 6 Trials). 
Particular attention should be paid to ensuring that interventions can produce effects 
with lasting benefit for children and adolescents, and significant efforts need to be made to 
develop or adapt interventions so that they can be used across a range of settings and can be 
accessible on an international scale173 (see Part 2, Mental Health Worldwide). Preventive, 
early intervention approaches for mental health problems face particular challenges in terms 
of demonstrating effectiveness and being applied consistently and thoughtfully to everyday 
practice in healthcare, however they offer huge potential for health benefit. The examples 
considered above provide optimism for future developments, but we need to look carefully at 
the limits of effectiveness, and also at the potential for harms caused (for example, potential 
negative effects of screening and classifying high risk groups and unnecessary treatment 
offered to young people with only temporary distress or symptoms, or harmful side effects of 
individual psychological treatments) (panel 11). Insights should be pooled across the age 
spectrum from the early years to older adults. Whilst there is still a long way to go before we 
have widely available and effective methods of prevention for mental health problems, the 
rigorous and sustained application of psychological science approaches to these areas of 
practice offers enormous promise. 
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Panel 11.  Research questions in prevention and early interventions 
 When are the optimal times to intervene to prevent mental health problems? 
 Who are the key “at-risk” groups to most effectively aim to intervene early or 
preventatively with? 
 What are the potential harmful effects of specific early intervention approaches? 
 How do we increase the “stickiness” of treatment effects – how do we make them 
last beyond the end of treatment? 
 How can we deliver interventions on the scale (including internationally) needed to 
reach at-risk children and youth? 
 How can insights from mechanisms of change help prevent or delay disorders, and 
reduce the recurrence of episodes? 
 How can we apply insights about prevention across the life span? 
Part 5 Technology: Can we transform the availability and efficacy of psychological 
treatment through new technologies? 
Introduction 
Internet-based psychological treatments have been applied across a broad range of mental 
health disorders. The rise of eHealth and mHealth approaches that use information 
technology (e.g., the Internet, virtual reality, serious gaming) and mobile and wireless 
applications (e.g., text messaging, apps) marks a new era for psychological assessment and 
treatments. In brief, technological innovations offer considerable possibilities to innovate 
psychological treatments, to adjust them to daily life and to the persons using them, and 
improve access to treatment. Such knowledge could be used to better understand how 
therapies work and to make them easier to use, so that more people can benefit from 
psychological treatments. Developments should be theory driven and properly evaluated. 
 
Internet-based psychological treatments 
Most psychological treatment research has been conducted with what could be called 
“traditional” Internet interventions. In these interventions, patients sit behind their computer 
and work through self-help materials, learning how to apply a psychological treatment to 
themselves with the help of a coach or psychologist101. Such self-help materials have often 
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been very close in content to face-to-face delivered psychological therapy (e.g., CBT). 
Accordingly, it is as if hard-copy paper manuals are simply converted to computerised form 
sometimes with simple additional content such as video clips. Direct comparisons between 
face-to-face interventions and guided Internet interventions suggest that there are no major 
differences in efficacy between the two treatment formats110. The efficacy of Internet-based 
therapies (see panel 12) has been shown for a broad range of mental health problems:  
depression174, anxiety disorders175, sleep problems176, bulimia175, and alcohol problems178. 
Panel 12. What Do We Mean by New Technologies? 
 Internet intervention: can be defined as any therapy that is delivered with the help 
of technology (for example through chat sessions, skype, or email), but most 
research has focused on Internet-based self-help interventions, so we focus on these 
treatments. If we refer to Internet interventions, we mean these treatments, unless 
we explicitly say otherwise. 
 A self-help intervention can be defined as a psychological treatment in which the 
patient takes home a standardized psychological treatment protocol and works 
through it more or less independently. Self-help interventions can be delivered with 
(guided self-help) or without human support (self-guided) 
  
 eHealth: the transfer of health resources and health care by electronic means 
(http://www.who.int/trade/glossary/story021/en; accessed April 15, 2016) 
 mHealth: The use of mobile and wireless technologies to support the achievement 
of health objectives180. 
 
Internet interventions have many advantages. They can save therapist time, reduce waiting 
lists, allow patients to work at their own pace, abolish the need to schedule appointments with 
a therapist, save travelling time, reduce the stigma of going to a therapist, and ease 
psychological help for individuals who are hard of hearing181. Furthermore, they might reach 
patients who cannot be reached with more traditional forms of treatment. Interventions  can 
be relatively easily adapted to specific target groups, with a wide range of attractive audio-
visual information with voices giving instructions in whichever gender, age, accent, 
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language, and perhaps game format the patient prefers. Internet interventions are also 
probably more cost-effective than face-to-face therapies, but more health economic research 
is needed to verify this. 
From a research perspective, Internet interventions have numerous advantages. One 
major advantage is that recruiting patients and conducting RCTs of Internet interventions is 
much easier and more cost effective and efficient than conducting RCTs of traditional face-
to-face psychotherapies (see Part 6, Trials). Larger randomized trials make it easier to 
examine effective components of interventions in dismantling studies, to examine moderators 
of outcome, and to examine mediators and the working mechanisms of therapies (see Section 
1, Mechanisms). Such research will stimulate the further development of personalized 
treatments of mental disorders by allowed larger scale trials powered to examine complex 
questions (see Part 8, Complexities) or to test for weaker effects (e.g. prevention trials).  
Internet interventions also have limitations. The quality of interventions that are 
offered through the Internet is not certain and despite portals for evidence-based Internet 
therapies such as Beacon (https://beacon.anu.edu.au), the possibility that low quality 
therapies are offered remains an important threat. Beacon is a webservice at which a panel of 
health experts categorise, review and rate websites and mobile applications and is part of a 
suite of self-help programs, developed and delivered by the National Institute for Mental 
Health Research at the Australian National University (although it is unfortunately not 
currently being updated). Drop-out rates are higher in Internet-based interventions than in 
face-to-face therapies183 and it is not known whether patients who drop out get worse because 
of the intervention. Internet interventions might affect the therapeutic alliance between 
therapists and patients, but most evidence suggests that therapies through the internet are at 
least equivalent to face-to-face therapy in terms of therapeutic alliance184. Relatively little 
research has focused on the long-term effects of Internet interventions (the same is true for 
face-to-face psychological treatments). We also acknowledge that Internet interventions 
might have unknown disadvantages, such as misunderstandings due to reduced 
communication channels in unguided interventions and schematization of contents. Data 
security as well as privacy should be well-guarded for any intervention that is offered through 
the Internet. Finally, despite increasing access, the Internet is not yet accessible to many 
potential users around the world, and dissemination will depend on the attitudes of possible 
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users and health care professionals. However, even in LAMIC countries access to the internet 
and/or mobile phone is expanding exponentially (see Part 2, Mental Health Worldwide), 
although creative solutions (e.g., regarding literacy) may need to be taken into consideration. 
 
Other technological opportunities 
Interventions can increasingly be offered through smartphones, smart watches, google 
glasses, virtual reality headsets, and all kinds of other innovative devices. Many of these 
devices have the advantage that they can be worn during daily life and can also collect 
information during daily life (ecological momentary assessment)185 (see also Part 8, 
Complexities). Such information might considerably improve prediction models for 
individual patients and thus potentially improve treatments and increase the effect sizes of 
existing treatments. Computerized Adaptive Testing techniques assess symptoms online with 
greater sensitivity and specificity from fewer items than traditional forms of outcome 
monitoring such as pen and paper questionnaires186. Several virtual reality treatments have 
been developed, mainly for anxiety disorders,. Patients are not confronted with the real 
anxiety-provoking stimuli but with their virtual counterparts using real-time computer 
graphics, body tracking devices, and other sensory input devices,187 with some evidence of 
effectiveness, 188 although many of the trials are small and of suboptimal quality. A 
considerable number of studies have demonstrated that telephone-supported therapies are 
effective in the treatment of common mental disorders190. 
There is a rapid proliferation of mental health ‘apps’ which offer a range of 
psychological interventions,191however, most lack health behaviour theory and evidence for 
the effectiveness192. Future research must develop theory-driven interventions and evaluate 
their effectiveness - since the vast majority are yet to be tested in randomised controlled trials 
(although there are some exceptions)193,194 and may need specific adaptations to the design of 
randomized trials because of rapid technological developments195. Widely available and 
untested products pose risks to the public. In this young field, while efforts have started, 
international approaches are needed to develop regulated approaches and procedures.  
The format of new technologies may allow new treatment techniques to be developed 
that were not part of pre-existing face-to-face psychological treatments but offer novel 
information processing options (e.g., virtual reality exposure, and possibly interpretation bias 
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training). Serious gaming, such as the Sparx program, also opens opportunities for 
interdisciplinary research and new methods of treatment delivery196. Serious games refer to 
those games with a purpose other than providing entertainment, in this case the delivery of a 
psychological treatment using game principles. Sparx is an interactive fantasy game designed 
to deliver CBT for the treatment of adolescents seeking help for depression. 
At some point, the automated support of these new technologies might in some cases 
replace the therapist altogether (‘therapist-free therapy’197), and lead to better, personalised 
treatments (see also Part 8, Complexities). New technologies can also be useful in predicting 
the development and outcome of mental disorders. For example, mobile phones are available 
to monitor relationships between psychological risk and suicide ideation198, and there is 
evidence that certain phrases and the use of personal pronouns for example predict depression 
status in blogs (see also Part 9, Suicide), although we acknowledge that this may raise ethical 
concerns198. Because enormous quantities of data can be collected through mobile phones and 
other devices and can be connected with existing databases, datamining techniques may be 
helpful to predict the onset and course of mental disorders. Such data could aid the 
development of innovative psychological interventions that are much more integrated into the 
new technologies which are assimilated into the daily lives of patients. However, technology 
and data alone will not suffice – endeavours are more likely to succeed if they are embedded 
in a sound theoretical framework to drive hypothesis alongside clinical knowledge. 
Finally, eHealth and mHealth approaches that use information technology (e.g., the 
Internet, virtual reality, serious gaming) and mobile and wireless applications (e.g., text 
messaging, apps) are examples of ways in which technology has been harnessed to innovate 
psychological treatments, their availability and evaluation. Technological advances need to 
go along advances in psychological theory and understanding of mechanisms of change. 
Future technological innovations offer considerable possibilities to innovate psychological 
treatments (see Panel 13), to adjust them more to daily life and to the persons using them, 
and to use the knowledge to better understand how therapies work and to make them better 
and easier to use, so that more people can benefit from psychological treatments across the 
age range and worldwide.  
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Panel 13. Example directions for Future Research with New Technologies for 
Psychological Treatments 
 Treatment and theory development: health behaviour theory informed technological 
treatment innovation across all areas of psychological treatments 
 Treatment evaluation: trials to evaluate the effectiveness of new products such as 
apps 
 Learning: Maximising and innovating learning methods during psychological 
treatment by fresh means of for example skills learning, habit change etc (e.g., via 
Serious Gaming) 
 Devices: the use of new technologies, like avatars, smart watches, Google glass, 
and other devices into existing psychological treatments to facilitate delivery and 
improve outcomes 
 Harnessing new technologies to advance methods by which to examine causal 
mechanisms,  refine treatments, and derive mechanistically-driven treatment 
approaches 
 Health monitoring: to enable big data capture to predict the onset and course of 
mental disorders 
 Personalisation of technology based interventions 
 Technologically aided preventative treatment approaches adapted across the age 
range 
 
Part 6 Trials to evaluate psychological therapies 
Introduction 
Several key issues in the design and conduct of clinical trials for the evaluation of 
psychological therapies must be addressed in the development of evidence-based 
psychological therapies. These issues present specific challenges, given the complexities of 
both the therapies being evaluated and the populations who are receiving them, as well as a 
number of opportunities for improvement. The challenges include improvements in standards 
for reporting clinical trials, specification of treatment protocols and inclusion/exclusion 
criteria, choice of outcome measures, measurement of adverse effects, and prevention of bias 
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in trial design and analysis. The opportunities include the increasing role of service users and 
carers in all aspects of trial design and conduct, the developing methodologies for achieving 
consensus regarding research questions and outcome measures, the development of new 
methods for analysis of mediators and mechanisms, and innovations in design of clinical 
trials (such as adaptive trial designs and mixed methods approaches that embed qualitative 
studies). 
 These challenges and opportunities will be considered in the context of a current 
feasibility study (the COMPARE trial, ISRCTN06022197) and the potential for a subsequent 
trial to evaluate CBT for people with psychosis in direct comparison to antipsychotic 
medication and a combined treatment, which is a research recommendation in the UK NICE 
guideline for treatment of psychosis in children and young people199. This trial is complex 
and challenging to conduct for a variety of reasons that will be described, and as such, 
illustrates many of the problems and potential solutions.  
Other important issues for psychotherapy trials include the selection of control 
conditions and outcome measures, the role of public and patient involvement, the inclusion of 
moderation and mediation analyses to facilitate identification and refinement of mechanisms 
and the development of new, innovative methods that are fit for purpose to answer the 
important questions that have been identified (see also panel 14). 
Panel 14. What Terms are Used in the Context of Clinical Trials? 
 Clinical trial: An experiment to determine whether a treatment works, usually 
determined by examining effects on outcome measures. This can include: 
- A feasibility study:  a small trial conducted to determine whether a larger 
clinical trial can be done e.g. capacity to recruit a specific sample[Joan: this is 
tautologous, can you give some examples of what might be tested for 
feasibility?]. 
- A pilot study:  a small trial that focuses on evaluating the trial processes, such 
as recruitment, randomisation, treatment protocols and follow-up 
assessments. These trials can be internal pilots, where the data collected 
contribute to a larger trial assuming there are no changes required, or an 
external pilot, where the data are analysed and set aside.  
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- A randomised controlled trial: a study in which participants are allocated to a 
particular condition (usually a treatment ‘arm’) on the basis of random 
assignment to produce an equal distribution of measured and, crucially, 
unmeasured variables. Ideally, treatment allocations are hidden from 
recruiters, participants, and assessors. The ‘controlled’ nature refers to using 
comparators (the conditions to which an intervention is compared); these 
often include the best available treatment, treatment as usual (what routinely 
happens in clinical services), a treatment designed to control for factors such 
as empathic human contact or a treatment with the putative ‘active’ ingredient 
removed (known as ‘dismantling’ designs). 
 Clinical Trials Units: specialist units that have expertise in centrally coordinating 
multisite clinical trials, in addition to trial design, data management, and trial 
statistics and health economics 
 CONSORT: The Consolidated Standards of Reporting Trials (CONSORT) 
Statement is an evidence-based guideline200, based on a systematic review of 
evidence regarding aspects of trial design and conduct that could contribute to bias. 
Using consensus methods, the developers produced a checklist of 25 items and a 
flow diagram, which aims to minimize bias and improve reporting of clinical trials 
 Sources of bias: many potential sources of bias can influence the validity of a 
clinical trial. These include allocation concealment (whether future randomization 
could be guessed), adequate blinding of participants, personnel, and outcome 
assessors (although the first two of these are nearly impossible to achieve in a trial 
of face-to- face talking therapies), amount of missing data and selective reporting of 
outcomes 
 Blinding: This refers to whether participants or staff are aware of the treatment 
allocation. Note single blinding versus double blinding is a key difference between 
psychological versus pharmacological trials.  
 Protocolised treatment: an attempt to standardize the delivery of a psychological 
therapy,  often characterized by required processes, procedures and milestones as 
well as those that are prohibited. Some treatment protocols are very specific, 
prescribing the content of each session in a strict, at times modularised manner, 
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whereas others are more flexible in order to account for the idiosyncratic, often 
complex, nature of presenting difficulties. The more rigid a trial protocol is, the 
easier it is to assess treatment fidelity and allow replication of the study. 
 
 
The need to improve clinical trial methodology 
Clinical trials are the cornerstone of evidence-based approaches to decisions about access to 
healthcare but in the field of mental health, such trials often have significant methodological 
shortcomings that result in low quality evidence. Many psychotherapy trials are not registered 
in an international database before recruitment starts201. This means that we cannot be certain 
that the  outcomes reported were those originally intended, and raises the possibility of 
selective reporting of outcomes (i.e., focusing on those that were statistically significant), or 
even that negative trials remain unpublished. Many psychotherapy trials did not attempt to 
maintain blinding in the raters,201which increases the likelihood of bias; treatment protocols 
were broad and not based on a specific model, which makes assessment of fidelity and 
replication problematic. These limitations could be overcome by ensuring linkage between 
expert trial methodologists and statisticians and innovators in psychological therapy 
development. Accredited Clinical Trials Units, with their extensive experience of trial design 
and conduct, could coordinate with academic methodologists who are at the cutting edge of 
developments in trial statistics and methodologies202. In the past decade, for psychological 
treatment trials, there has been substantial improvement in the adoption of clinical trial 
registration and pre-specification of primary outcome including CONSORT criteria (panel 
14). Such procedures are increasingly required by the leading journals and by ethical review 
boards. Particular adaptions for psychological trials need to be developed, e.g., around issues 
such as double blinding which cannot be maintained with a therapist-delivered psychological 
treatment. 
 Relatedly, the potential negative effects of psychotherapy are increasingly being 
recognised and there is a need to document unwanted effects and report serious adverse 
events (SAEs) that are reported to ethics committees as part of safety monitoring. 
Historically, trials of psychological therapies have been poor at both monitoring hypothesised 
side effects and deterioration and reporting SAEs207. Negative effects that require recording 
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range from worsening of existing symptoms to issues such as novel symptoms, poor 
therapeutic relationship, and perceived coercion203. Such adverse events are present in both 
traditional psychotherapies and internet-based interventions204. A procedural model and 
checklist are available for clinicians and researchers, and the detection and management of 
such adverse events in treatment trials is considered a sign of good rather than bad practice205. 
Formalized measures of possible harms (side effects) of treatment trials should be the rule 
rather the exception in psychotherapy research (see206,207).   
 To ensure that psychological therapy trials are credible, it is important to meet 
the minimum standards expected from other fields (e.g., pharmaceutical trials). However, we 
also have an opportunity to develop our own standards, which could ensure superior trial 
design, conduct and reporting, that other fields could aspire to meet. Since the introduction of 
the CONSORT guidelines, 200   many researchers who have studied psychological therapy in 
trials have embraced trial registration, pre-specification of statistical analysis plans and trial 
protocols, independence of statistical analyses from the psychological innovators and 
adherence to CONSORT’s reporting recommendations . Yet, not all criteria can be met given 
that, for instance, double blinding in these types of studies is not usually possible.  However, 
double blinding can be problematic for pharmacological treatments – despite best intentions, 
aspects of the treatments can break the blind, for example the rapid and dramatic weight gain 
and parkinsonian side effects with both first and second generation antipsychotics. Another 
possibility is that subjective cognitive effects208 unblind participants.  
A set of reporting standards specifically tailored to psychological therapy trials are 
being developed as an extension of the original CONSORT guidelines209. These include 
recommendations to improve internal and external validity, address measurement issues 
(psychological therapy trials often have many measures, many of which assess latent 
constructs), improve reporting of recruitment processes and representativeness of participant 
samples and increase contextual information such as factors that helped or hindered the 
interventions. More broadly, further research on trials methodology (for example, on how to 
deal with the issue of blindness) will be an important area of future enquiry.  
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The conduct of a clinical trial by the developer of a psychological therapy  could be 
considered equivalent in terms of bias to industry-sponsored trials of pharmacological 
therapies and investigator allegiance effects have been observed in psychological therapy 
trials210, 211. A focus has been more on allegiance to a given type of psychotherapy than 
finance.  The obstacles to obtaining funding to conduct the trial are likely to be greater for 
psychological therapies than for industry-sponsored pharmaceutical trials, and although trials 
of psychological therapies may be conceived and conducted by the originator, they are rarely 
funded by the originator. Steps can be taken to reduce bias, such as  a declaration of interests 
(personal financial interests such as training fees, book royalties and non-financial interests), 
the registration of protocols, pre-specification of statistical analysis plans, and involvement of 
independent methodologists in trial design and data analysis. Trial Steering Committees and 
Data Monitoring Committees with independent clinical, statistical and service user 
representation also increase confidence and minimise bias. These committees can provide 
constructive criticism and protect the safety of participants and the scientific integrity of the 
trial. Expertise in all relevant approaches is important for trials that compare two or more 
therapies; for example, the COMPARE trial team includes expertise in both CBT and 
antipsychotic medication. 
 
Inclusion and exclusion criteria 
The selection and justification of inclusion and exclusion criteria are vital to good trial 
design. They should be specific enough to allow the identification of suitable participants and 
replication of a trial, but broad enough to reflect real world clinical settings and permit 
generalisability, according to the purpose of the trial. Historically, many psychological 
therapy trials require a single diagnostic category or symptom as an entry criterion, not 
allowing several or at least specific comorbid conditions (e.g., other mental health problems, 
physical health issues, drug or alcohol use). This is difficult to justify when the clinical reality 
is one of complexity, with comorbidity being the norm (see also Part 8 Complexity). More 
recent trials that have evaluated CBT for psychosis have, in general, been good in terms of 
generalisability, allowing for inclusion of participants who meet such broad criteria(this is 
also true for trials of psychological therapy for depression212). Even trials that have focused 
on mechanisms of change, such as whether reducing worry processes results in reduction in 
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paranoid thinking, have allowed comorbidities213. However, there may be a trade-off between 
clinical pragmatism (broad entry criteria) and the ability to scrutinise specific mechanisms 
within a trial. One exception to this is trials that attempt to address transdiagnostic processes 
by targeting a specific mechanism, such as modification of attentional biases or extended 
perseverative processing, or a specific problem, such as sleep difficulties or irritability, across 
diagnostic groups. This approach offers potential advantages in terms of recruitment, 
generalisability and implementation in services (see Part 8 Complexity, for further discussion 
of these issues).    
Better integration of research trials within clinical settings would facilitate the 
generalisability of results to the real world. One goal is for every individual who attends a 
hospital clinic, engages with a community mental health team or attends an appointment in 
primary care to be offered participation in psychological therapy research (if willing and able 
to provide consent). For example, in cases in which there are genuine uncertainties (e.g., what 
‘dose’ of CBT for psychosis is required), all willing participants could be randomised to 
different treatment duration options. 
 
Choice of control condition 
There is considerable debate about appropriate control conditions; for example, many argue 
that “treatment as usual (TAU)” is not appropriate since it may be highly variable and at 
times include access to the treatment being provided in the experimental arm. The use of an 
active control condition, which reduces confounds of nonspecific factors such as attention, 
warmth, human relationships, is often recommended; however, this may oversimplify the 
issue of therapeutic relationship – itself a topic of research enquiry and debate about its 
importance. The provision of an alternative therapy can raise other confounds such as the 
‘match’ between therapist and participant and the ability of a therapist to switch between, and 
adhere to, different treatment protocols when it is likely they have greater skill and allegiance 
in relation to one or the other. There are ways to deal with such issues – for example, multiple 
therapists providing each active treatment condition214, perhaps across trial sites, such that 
different trial sites have different expertise/allegiance but deliver all therapiesFurthermore, 
there may be differences between conditions in the effectiveness of psychological placebos. 
For instance, the effects of non-directive supportive therapy are comparable to CBT and 
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interpersonal psychotherapy for depression217, although CBT is superior in the case of 
psychosis218.  
Clinical psychological trial experts such as Kazdin have formulated models to guide 
the type of trial needed to address the type of question asked – and this is a ripe area for 
continued methodological development. Design solutions will depend, in part, on the specific 
research question; for example, if the pragmatic question is whether something works better 
than current provision, then a two-arm trial for comparison against a specified and 
protocolised treatment as usual that utilises best current practice may be ideal (for example, 
CBT plus monthly engagement and monitoring of current difficulties compared to monthly 
engagement and monitoring alone219). If the question is whether one form of psychotherapy is 
better than another, then a head to head comparison may be required. If the question is why a 
treatment works or whether a specific element is necessary, then a therapy which controls for 
specified factors (such as human contact) but in which the active ingredient has been 
removed may be. Findings from meta-analyses suggest that waiting list controls should be 
avoided, since they can lead to inflated effects sizes for the experimental treatment, possibly 
by leading people to abandon efforts to solve problems or recover independently because 
they are waiting for therapy43. 
 
Outcome measures 
Most trial methodologists would recommend a single primary outcome and a single time 
point pre-specified at which this main outcome should be measured  (e.g., total symptoms at 
final follow-up assessment) which can sit uncomfortably with basic aspects of psychological 
assessment – such as the need for multiple assessments of a construct for validity and 
multiple time points for reliability, as well as to track the time course of the response. 
However, there may be times when more than one primary outcome is justified (e.g., in 
psychosis studies, clinicians prefer psychiatric symptoms whereas service users prefer social 
outcomes), 220 although it is important to note that multiple primary outcomes have 
consequences for power calculations, requiring larger sample sizes. In addition, maximising 
the use of data obtained at multiple time-points in order to obtain the most accurate estimate 
of treatment effects over the full follow-up duration can be achieved by specifying an 
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analysis involving all available data for a particular measure, which may be preferable to 
anchoring judgements regarding efficacy to a single assessment point. 
There is often debate about which is the most important outcome. For people with 
psychosis, there is debate regarding whether clinical outcomes (e.g., psychiatric symptoms) 
or social outcomes (e.g., recovery, social functioning and quality of life) are the most 
important. The answer to this question largely depends upon who is asked, such that 
clinicians often prefer the former and service users prefer the latter220 Consensus regarding 
outcome measures for a specific condition would enable individual participant data meta-
analyses221-223, which can hopefully inform the moderators and mediators of treatment 
response (i.e., what works for whom; see also Part 8, Complexities). Integration with and 
adoption of routinely collected service outcome data would also facilitate this. As part of a 
UK initiative that aims to establish agreement about core outcome sets for particular health 
conditions (COMET: http://www.comet-initiative.org/about/overview), there is work 
underway to establish consensus about a core outcome set for evaluations of interventions for 
people with psychosis224. It is unclear whether a detailed interviewer-administered rating 
scale, which may provide rich data and be more engaging for participants, or a self-report 
measure, which may be more reliable (since there is no need for inter-rater reliability across 
sites and staff) and avoids rater bias, are preferable. A combination of both, so long as they 
are clearly pre-specified as dual primary outcomes, could represent a reasonable solution that 
maximises the benefits of both approaches. If a trial with dual primary outcomes 
demonstrated consistency across them, this would increase confidence in findings. 
Another important consideration when selecting outcomes is the time required to 
complete the overall battery of assessments. Psychological therapy trials often include 
numerous secondary outcome measures, which might be of significant interest. However, the 
greater the assessment burden on participants, the more likely it is to impair retention in the 
trial and subsequently result in missing data in the outcomes, reducing the internal validity of 
the trial. Limiting the selection of outcome measures is likely to minimise attrition, but  limits 
opportunities for understanding processes of change. Similarly, agreement regarding the 
frequency of assessment occasions and length of follow-up would facilitate the pooling of 
data and the capacity for comparisons across trials. There is a trade-off between collecting 
meaningful data that will permit identification of what works for whom across a broad range 
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of outcomes and facilitate mediation and moderation analyses, and ensuring that participant 
retention is not jeopardised. The involvement of service users who would be eligible for trial 
participation in trial design, as well as ensuring pilot and feasibility work has been done, are 
both likely to be useful strategies in achieving this balance. Another possibility for 
minimising burden and maximising both ecological validity and multiple measurements of 
outcomes is to use experience sampling method or ecological momentary assessment data as 
outcomes. This would allow reporting of symptoms, emotions and indicators of functioning, 
such as time use in daily life, as primary outcomes in clinical trials (see Part 8 Complexity).  
 
Public and patient involvement 
Public and patient involvement226, 227 is another area that can help to improve the conduct of 
psychological therapy trials. People with mental health difficulties can obviously provide 
unique insights into clinical trials, including identification of the most important and relevant 
research questions and thus outcome measures. For example, a definitive trial of CBT 
compared with antipsychotics would need to decide whether the most important question is 
one of superiority (e.g., is combined therapy superior to monotherapies), one of equivalence 
(which would enable choice), or non-inferiority (which may indicate one treatment or another 
given the differences in adverse effect profiles, although this will always be dependent on 
individual choice, since what is an acceptable side effect will vary considerably between 
people). The assessment of acceptability of psychological therapies, as well as exploration of 
potential adverse effects, can be informed by embedded qualitative interviews and analyses 
that can be user-led (again, the COMPARE trial incorporates such a study). Finally, the 
involvement of service users as staff and, ideally, co-applicants and investigators, should 
ensure meaningful participation in all phases of trial design, conduct and reporting 
(COMPARE has two service user co-investigators/grant holders).  
Public and patient involvement can be via consultancy groups (which was the case for 
the COMPARE trial), via priority setting partnerships that identify and prioritise the top ten 
unanswered questions (the James Lind Alliance facilitate the development of such 
partnerships; see http://www.jla.nihr.ac.uk/ )which has been done for the treatment 
uncertainties related to a diagnosis of schizophrenia228, or by the use of Delphi methods to 
establish consensus on topics with experts by experience (the COMPARE trial was also 
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informed by Delphi studies of people with psychosis on both defining recovery229 and 
identifying treatment priorities and preferences230). 
 
Mechanisms and mediators of change 
Trial design should also attempt to facilitate the identification of potential mechanisms and 
mediators of change (see Part 1, Mechanisms), as well as moderators of treatment effects - in 
order to inform how a treatment works, what components are necessary and sufficient, and 
what works for whom. This approach will improve and refine treatments, make them more 
efficient, and permit true informed choice for service users and carers. The identification of 
mechanisms could be built into all clinical trials, which would allow pooling of data, 
although this would also require consensus among researchers about the instruments that 
should be included in the trials. When a specific research question involves testing a 
mechanism, the trial must have sufficient statistical power for the mechanistic hypotheses as 
well as any between-group predictions. 
The identification of mediators and moderators requires considerable thought at the 
planning stage to ensure that the appropriate factors are measured at the appropriate time 
points. The development of new statistical methods for the analysis of mediation and 
moderation should help with the accurate identification of mechanisms of change and 
mediators of treatment outcome. Traditional approaches to mediation analysis231 assume that 
confounding due to an unmeasured variable being responsible for changes in both mechanism 
and outcome is absent, which is problematic. More recent developments, such as attempting 
to measure and adjust for all important confounders,232 or attempting to effectively adjust for 
unmeasured confounders (hidden confounding) using instrumental variable-based methods 
employing analyses based on principal stratification,233 might be better suited to this purpose. 
Recent examples relevant to CBT for psychosis include the finding that participants with a 
psychosocial causal explanation of their difficulties may be more likely to engage with and 
benefit from CBT234 and that participants with a good therapeutic alliance with their therapist 
are likely to benefit from a higher number of CBT sessions, whereas those with a poor 
alliance may be more likely to experience harm from a higher number of session235 (see Part 
8, Complexity for a related discussion regarding personalization.) 
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Innovation in trial design and methodology 
The wider context surrounding an individual trial is important to consider. The reliability and 
validity of the findings from meta-analyses that are used to inform policy, guidelines and 
service recommendations are largely dependent upon the quality of the trials that are included 
and the suitability of the selection criteria (i.e., whether the included trials were designed to 
answer equivalent questions). Therefore, designing high quality trials with a view to the 
longer term perspective provides an opportunity to improve such meta-analyses. 
Collaboration between research groups, investigators, and methodologists with regard to 
future pooling of data could be facilitated by the establishment of collective research groups 
recognised by group authorship, which would incentivise such involvement and co-operation.  
At times, there is a need for alternative approaches to the traditional two-arm 
randomised controlled trial, such as multi-arm multi-stage trials236.  
New methodologies, including adaptive designs, preference trials, and sequential, 
multiple assignment, randomised trials (SMART trials), will permit better generalisability to 
routine practice and more ethical and efficient trial conduct. For example, a SMART 
permitting re-randomisation for non-responders to CBT or antipsychotics to the other 
monotherapy or the combination, after a relatively short period of time, would confer future 
clinical advantages such as more rapidly arriving at a suitable treatment for an individual.  A 
preference trial would maximise recruitment in a field in which both service users and 
clinicians may have strong treatment preferences and opinions about talking therapy or 
medication that would jeopardise recruitment, generalisability or adherence to allocation in a 
standard RCT. An adaptive design with a planned and pre-specified interim analysis may 
permit the early abandonment of an arm that proved to be inferior. Cohort multiple 
randomised controlled trial design239 allows several RCTs to be conducted simultaneously 
within a larger cohort or register of patients. For each RCT, all eligible people in the cohort 
are identified, and then some are randomly selected to be offered the experimental 
intervention. The outcomes in the randomly selected participants are then compared with the 
outcomes in those who were eligible but not selected (i.e. receiving standard care or treatment 
as usual). Such designs could overcome recruitment difficulties, and increase statistical 
power, efficiency, representativeness of samples and comparability between trials, as well as 
increasing knowledge about the natural course of mental health problems and the likelihood 
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of collecting data on long term outcomes. This approach would be ideally suited to mental 
health problems that are seen within specialist teams (e.g. eating disorders or first-episode 
psychosis), especially when the teams are linked within a national or international network 
and routinely monitor outcomes in a standardised way. In all cases, collaboration among 
experts in trial design and analysis, experts in the development of psychological therapies and 
experts by lived experience will be essential. 
Better detection of responders and non-responders would allow us to identify what 
works for whom (see Part 8, Complexity); this could be achieved by ensuring better selection 
of measures, incorporation of experience sampling or momentary assessment in the early 
phases of a trial (see Part 5, Technology), use of improved inclusion and exclusion criteria 
and the development of statistical methods for mediation, moderation and consideration of 
individual response trajectories rather than aggregate effects. 
Finally, it is important to recognise that research to identify successful interventions is 
not just about RCTs, and clinical trials should complement other types of research questions 
and evidence. An example of this is the need for RCTs to include embedded qualitative 
studies that seek to obtain rich data that will allow triangulation with quantitative outcomes as 
well as inform our understanding of active treatment processes and the generation of new 
hypotheses to test empirically. The COMPARE trial involves interviewing participants about 
their experiences of both CBT and medication, focusing on acceptability, credibility, and 
wanted and unwanted effects (these interviews are designed, conducted and analysed by 
researchers with lived experience of psychosis), which has the potential to inform the design 
of a definitive trial in relation to selection and recruitment of participants, entry and exclusion 
criteria, outcome measures, and treatment protocols.  Another example would be developing 
methodologies for pragmatic studies in  real world settings that encompass co-morbidities 
both mental and physical and allow us to move beyond standard RCTs.  
 
Finally, if all of the above can be achieved, this will increase our ability to identify and 
answer the most important questions, conduct trials with greater reliability and validity and, 
increase the confidence in and acceptance of their findings (see panel 15). Developments in 
three areas could dramatically improve trial quality in the evaluation of psychological 
therapies.  Meaningful involvement of service users and carers will allow us to identify the 
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appropriate research questions and methods, ensure relevance of outcomes (including adverse 
effects), and improve retention of participants. Finally, creation of large scale data sets, 
whether by consensus regarding design considerations and measures that enable pooling of 
data, developments in individual participant data meta-analyses, or the use of routinely 
collected service data, will enhance the credibility of the results of our clinical trials. 
Psychological treatment trials stand to benefit from advances in trials in other areas of 
medicine. Increased attention to and innovation in clinical trial methodology is to be 
welcomed.  
 
Panel 15. Directions and Priorities for Future Research in Clinical Trials of 
Psychological Treatments 
 We need to establish consensus amongst stakeholders (the innovators and 
developers of psychological treatments, service users and methodologists) 
regarding outcome measures, appropriate scheduling of assessments and length of 
follow-ups 
 We need to routinely build into the design of clinical trials the ability to analyse for 
mechanisms (see Part 1, Mechanisms) 
 We need to engage with commissioners and providers of psychological services to 
maximize the likelihood that such services can facilitate the collection of data and 
build in trials where there is uncertainty 
 We need to ensure quality trial design and valid, reliable analysis of data by routine, 
early engagement with Clinical Trials Units, trails registration for all trials 
including production of pre-specified Statistical Analysis Plans, and ensure that 
data analysis adheres to such plans and is conducted by independent specialists in 
trial statistics 
 We need to involve service users in all aspects of trial design and conduct, from 
decisions regarding research questions and methods, through to involvement in trial 
management and governance, research administration and interpretation and 
dissemination of findings 
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 We need to carefully match comparators to the specific research questions that 
trials are seeking to answer 
 We need to measure unwanted effects as well as wanted effects, and arrive at a 
consensus about how to measure and report adverse effects 
 We need to increase our use of innovative trial designs that maximize value for 
money, value for participant input and reflect clinical practice; such designs include 
adaptive trials, multiple trials within cohorts, SMART trials and preference trials. 
Different designs will be suited to different research questions and clinical contexts 
 We  need to encourage career paths for those focussed on advancing methods in 
psychological treatment trial design methodology, statistics and so forth 
 
Part 7 Training: Can we foster a vision for interdisciplinary training across mental health 
sciences to improve psychological treatments? 
 
Introduction 
In this section we discuss why we should endeavour to improve the links between clinical 
psychology, psychiatry, and basic research training, and make some proposals about how this 
might be achieved. We review some early successes in innovation in psychological 
treatments when basic researchers and clinicians have worked together, and discuss the 
reasons that such fruitful interaction has decreased in recent years. We offer some concrete 
recommendations to bridge the gap between clinical practice and basic research relating to 
psychological interventions. 
 
Historical shifts in interdisciplinary training 
In 1949, the American Psychological Association convened the famous Boulder 
(Colorado) Conference on Graduate Education in Clinical Psychology, in order to agree on a 
standard model for clinical psychology training in the USA. Heavily influenced by the ideas 
of David Shakow, it adopted a “scientist-practitioner” training framework that encouraged 
clinical psychologists to use scientific research to inform their treatment241. This influential 
proposal facilitated the development of effective new psychological interventions, which was 
catalysed by clinicians who performed basic research, and basic researchers who understood 
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the principles of psychological treatments. This confluence of expertise resulted in vital 
insights into the mechanisms of onset, maintenance and treatment of symptoms of mental 
health problems, and in some case completely revolutionised the psychological treatments 
available.  
For example, by taking a scientist practitioner approach, training in psychological 
treatment becomes far more than just learning to deliver the treatment described in a manual. 
By understanding the principles on which a treatment was derived this can help the 
practitioner best deliver the treatment and adapt to a given situation or patient. An example of 
where basic training is important includes the development of various types of exposure 
therapy (incorporating response prevention) for anxiety disorders, including phobias, PTSD 
and OCD, was initially derived from fear extinction research in rodents, which showed a 
reduction in Pavlovian responses to negatively conditioned stimuli when the aversive 
outcome was omitted242, 243 (see also Part 1, Mechanisms). Importantly, the focus on 
response prevention, i.e., encouraging patients suffering from anxiety not to engage in their 
usual coping strategies when confronted with an anxiety-provoking stimulus (for example, 
avoidance for phobias or rituals for OCD), came from the insight that these behaviours can 
maintain the conditioned association through preventing extinction244. This might appear 
counterintuitive to the patient because, acutely, the prevention of coping behaviours increases 
anxiety in the short-term, but leads to a reduction in anxiety in the long-term. Since this can 
also be counterintuitive from the perspective of some other therapeutic approaches, it can be 
important to understand the principles behind exposure techniques.  Another example of 
practitioners benefiting from understanding the underlying science via their training is in the 
context of depression; namely the influential “learned helplessness” model245, and its later 
modifications in relation to hopelessness246. This model originated from the finding that 
animals exposed to inescapable aversive stimuli subsequently failed to escape when they had 
the option to do so247. Learned helplessness theory made important contributions to our 
understanding of risk factors for depression, especially relating to the roles of attributional 
style and perceived controllability248. Moreover, it inspired numerous animal models that 
remain the mainstay of testing procedures for new antidepressant drugs in preclinical 
research, and translational research in this field has yielded valuable insights into the basic 
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cognitive and brain changes that underlie depressive symptoms and their response to 
treatment249. 
Over the past several decades the links between basic research, clinical psychology 
and psychiatry have become increasingly weak. There may be multiple reasons for this. One 
simple fact is that due to the rapid expansion of psychology, psychological treatment 
researchers and practitioners rarely work in the same building as, for example, social 
scientists, economists, neuroscientists or geneticists. This reduces the opportunity to interact 
and share ideas. Another important issue is that basic researchers and clinical psychologists 
often do not read the same journals, or even attend the same conferences, meaning that 
opportunities for interaction are limited2. 
 
Renewing the links between basic research and psychological treatments 
Clinicians providing psychological treatments need training in basic research 
In most countries, relatively little teaching of contemporary basic research (for example, 
experimental psychology, neuroscience, genetics, physiology, pharmacology, data science, 
social science, economics) is incorporated into the clinical syllabuses of clinical psychology 
or psychiatry, or of allied professional training in mental health treatment. The USA and 
Canada are notable exceptions, where many clinical psychologists complete a doctoral 
training programme of at least 5 years’ duration, which includes substantial basic research 
teaching together with an extensive research-based thesis, as well as clinical training. The 
basic science content provided to psychiatry trainees in the USA has been emphasised250, 
although there is recognition within the profession that further such training would be 
desirable251, 396396. Other than these examples, the basic research content included even in 
doctoral-level clinical psychology programmes (e.g., PsyD in the US/Canada, which is taken 
by approximately half of all qualified clinical psychologists in these countries; DClinPsy in 
the UK) is limited. In other countries, where a Masters degree is the standard educational 
qualification required to become a clinical psychologist (including most of the EU, Australia, 
New Zealand and South Africa), there is very little basic research content in the curriculum. 
This raises a serious concern about the training of clinical mental health researchers of 
the future. There is a risk that they will not be equipped with the tools to understand, 
critically evaluate and utilise basic research that might be relevant to the development of new 
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treatments or preventative strategies. A corollary to this is that there is a danger that 
psychological interventions may become “stuck in the past” – relying on outdated models 
that are not supported by contemporary research or theory. This disconnect hinders 
innovation, and the slow emergence of effective, truly novel psychological treatments in part 
attests to this. Unless clinical psychologists and psychiatrists are equipped with the skills to 
evaluate research on both risk factors (for example, genetic and socioeconomic influences) 
and proximal mechanisms (for example, cognitive and neural processing of information), it is 
difficult to know where to start thinking about improving preventative strategies and 
treatments.  
 
Basic researchers need training in clinical conditions and psychological treatments 
Most basic researchers, despite enthusiasm for the notion that their research might contribute 
to improved mental health treatments, have a very vague conception of what standard 
psychological interventions entail, as clinical practice is not generally taught even in 
undergraduate level psychology degrees. Specifically, many basic researchers have little 
knowledge of the evidence base supporting standard psychological treatments, and have little 
opportunity to interact with clinical psychologists, to see therapy in action, or to find out what 
the common techniques comprise. Indeed, the view that psychological treatments are 
primarily delivered in the context of an anti-empirical psychoanalytic couch tradition, and 
that they are not derived from solid scientific theory or supported by robust evidence from 
clinical trials, is worryingly prevalent among basic researchers in our experience2. To be able 
to formulate relevant research questions, basic researchers who are interested in contributing 
to the development of psychological treatments need to understand, at least at an elementary 
level, what the symptoms of mental health problems are (and are not), what the most 
commonly used and evidence-based psychological interventions entail, and how theoretical 
models guided their development, and which are the key questions to solve (and which are 
not) for the future.   
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Panel 16. An Example of How Linking Training in Neuroscience to Clinical Need 
Might Inform Psychological Intervention Development: Could Understanding 
Reward Processing in the Brain Help in the Development of New Treatments for 
Anhedonia? 
 Over the past decade there has been renewed interest in a core symptom of 
depression, anhedonia, which is the loss of interest or pleasure in previously 
enjoyable activities. Anhedonia is also an important component of many other 
mental health conditions including schizophrenia and addiction, as well as being a 
prominent symptom in neurological disorders such as Parkinson’s disease. In 
depression, anhedonia is associated with a more severe course of illness and poor 
response to standard antidepressant drug treatment252, and psychological 
treatmentss400. Clinicians appreciate this as an area of specific need in which 
current treatments are inadequate. 
 Given that anhedonia is intrinsically related to an absence of motivation and 
hedonic response, it has been proposed that this symptom may arise due to 
disruption of the brain’s reward circuits253, which have been characterised in 
extensive detail by neuroscience research over the past 30 years. This is not a new 
idea – in the 1970s Jeffrey Gray first proposed that symptoms of depression might 
be explained by changes in a “Behavioural Activation System” (BAS) and a 
“Behavioural Inhibition System” (BIS)254, although most depression researchers 
focused on the BIS and its relationship with neuroticism. However, an important 
conceptual advance since that time has been the notion that the reward system 
(BAS) comprises several relevant cognitive processes: hedonic response to reward 
delivery, valuation of rewards, reward learning, propensity to exert effort and 
decision-making. These components at least partially dissociate, and are associated 
with activation in different brain circuits and different neurochemical systems255. 
 
 This knowledge from neuroscience research has been exploited by clinical 
psychologists seeking to develop treatments specifically targeted at anhedonia, for 
example Positive Affect Treatment (PAT)255. This builds on Behavioural Activation 
therapy and Positive Event Scheduling, both effective treatments for depression256 
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that were originally motivated by ideas derived from behaviourism40, and that are 
known to increase responsivity in the brain’s reward system257. Drawing on the 
finding that reward processing comprises a diverse set of processes, the aim of the 
PAT package is to increase engagement in, attention to and anticipation of 
enjoyable activities16. Coming from a complementary angle, another novel 
approach based on cognitive science (here, the processes of mental imagery and 
interpretation bias) has been to use positive imagery training, which in trials has 
shown some effect in depressed individuals suffering from anhedonia258, 259 (though 
not depression overall) This type of focussed approach has been incoporated into 
the wider PAT package. While these novel interventions require further evaluation 
specifically in groups of anhedonic individuals, they provide examples of how 
scientific discoveries are being used to develop innovative psychological 
interventions.  
 
The future of interdisciplinary training 
Training clinicians in basic research 
How can we ensure that the next generation of research leaders, both clinical and basic, is 
able to bridge this growing divide? One priority is to provide more academic training 
opportunities for trainees and qualified practitioners, and to attract those with a strong 
aptitude for research. In the UK, although competition for places on clinical psychology 
professional doctorate courses is intense, and these recruit highly academically able students, 
very few subsequently develop a clinical research career. Funding opportunities for academic 
training of qualified clinical psychologists are highly competitive. That said, major UK 
research funding bodies, such as the National Institute for Health Research (NIHR) and 
Medical Research Council, offer academic training pathways for clinicians. These offer 
clinically qualified, non-medical healthcare professionals the chance to undertake a PhD, 
whilst covering a clinical-level salary, as well as tuition, travel and training costs, and 
research consumables MRC [Joan: leave here for Production to insert as margin links: 
http://www.mrc.ac.uk/skills-careers/fellowships/clinical-fellowships/clinical-research-training-
fellowship-crtf/ NIHR: http://www.nihr.ac.uk/funding/nihr-hee-ica-programme-CDRF.htm]. This 
provides a valuable springboard for a clinical research career, but there is scope for much 
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greater uptake by clinical psychologists, in part because they may not be aware of these 
opportunities or have sufficient support or research experience to develop a strong 
application. Another way of improving academic training in clinical psychology would be to 
create longer training programmes specifically for those trainees with a strong aptitude for 
research, similar to the North American PhD model, which would provide sufficient time to 
conduct an extensive research project as well as teaching relevant scientific material 
alongside clinical skills. The PCSAS model recently developed in the USA, which 
emphasizes the science of clinical psychology in training and internships, would also be an 
effective way of increasing research training opportunities. A similar training model exists in 
Australia, in which students are enrolled in a clinical training program and PhD program 
concurrently – and are awarded both degrees at the conclusion (e.g., Master of Psychology 
(Clinical) / PhD). This ‘combined’ degree is offered at The University of New South Wales 
(UNSW Sydney). 
We also need to develop training pathways for mental health researchers that foster an 
interdisciplinary approach, both between clinical psychology and psychiatry, and between 
clinical mental health disciplines and a variety of relevant basic research disciplines. One 
possibility would be to encourage clinical psychologists to undertake internships or 
placements in basic research settings across a range of relevant disciplines, from economics 
and social science to neuroscience and genetics. Psychiatrists in the UK already have such an 
opportunity through the NIHR Clinical Academic Fellowships scheme, but we are aware of 
no equivalent programme for clinical psychologists, in either the UK or other European 
countries. Multi-skilled clinical academics, trained in an interdisciplinary environment, would 
have the advantage of being able to ‘speak the languages’ of both clinical and basic research. 
They would also be best placed to develop the meta-professional skills needed to conduct 
truly interdisciplinary translational research, and to use the knowledge derived from basic 
research to drive innovation in psychological treatment development. 
 
Training basic researchers in psychological interventions 
Basic researchers with an interest in understanding and contributing to the development of 
new psychological treatments need to be provided with the opportunities to do so. In the same 
way that a first year neuroscience PhD student might learn about the principles and practice 
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of neuroimaging analysis, and therefore be able to evaluate neuroimaging evidence more 
effectively because they understand the potential pitfalls (even though they may never use 
this technique), basic researchers need a route through which they can learn about what 
psychological treatments are and how they are theorised to work. This would provide a new 
generation of researchers who understand the basic principles underlying psychological 
interventions and could bring a fresh perspective on driving innovation. Simply sitting in the 
same lectures and tutorials as clinical trainees would increase the opportunity for meaningful 
interaction, and encourage both clinical and non-clinical students to value input from the 
other in developing collaborations. While neuroscience and cognitive/experimental 
psychology students are obvious candidates here, students with backgrounds in a whole range 
of disciplines, from social science and economics, to computer science and mathematics, 
through to molecular biology and genetics, may have an interest in psychological 
interventions and be able to contribute important ideas. 
 
Culture change needed to accept more crossover 
At present there are structural obstacles to addressing the problems mentioned above that 
require bold changes in thinking to overcome. These obstacles are present in terms of both 
clinical accreditation and funding. A huge amount of research talent exists among mental 
health practitioners that is under-utilised, and perverse incentives, including a possible 
reduction in salary and a perception that research will not help career progression, often 
discourage clinicians from entering academia. Additionally, the procedures for obtaining 
funding for a research doctorate are not widely understood among trainees, and the 
opportunities to gain the research experience that would contribute to a competitive 
application are sporadic and invariably depend on locally available supervisors, meaning that 
the trainees with the most research potential may be overlooked. Finally, unlike for clinical 
training (at least in the UK), there is a lack of national recruitment for research training in 
clinical psychology. These obstacles could be addressed through targeted, longer programmes 
(similar to the PhD pathway in North America) that include a considerably more substantial 
research component to the professional doctorate (alongside standard clinical training), and 
recruit nationally in order to attract the trainees with the greatest research potential. More 
substantial research projects would also help to address the concern that learning about 
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techniques may be forgotten if not put into practice. Many European clinical psychology 
training programmes do successfully blend clinical training with basic research – although 
the relatively short periods of these Masters level programmes and lack of requirement for a 
doctoral level thesis mean that trainees do not receive the same level of research training as in 
the North American PhD model. For example, an interesting model of training clinical 
psychologists in recent years has been pioneered by Karolinska Institutet (Sweden). In this 
model, clinical education is based within the Department of Clinical Neuroscience, and 
within a medical university. This has resulted in high level of exposure to both psychology 
and neuroscience, as well as encouraged awareness of the rich links to physical medicine. 
Almost all the instructors are involved in research, and a majority have at least 50% of their 
time devoted to research. Although only a Masters level qualification is required to become a 
clinical psychologist in Sweden, Karolinska students are poised as a new generation of 
scientist-practitioners. The development of similar programmes elsewhere would be a 
positive step, as would an examination of the outcomes of different international models. To 
our knowledge, such an investigation has not been conducted to date, but would be extremely 
valuable.  
 
Models of shared research supervision 
Another major limiting factor is that those who do enter research training are often only 
supervised by clinicians, rather than by basic researchers. This divide cuts both ways – as 
discussed above, there are likewise very few opportunities for basic research trainees who are 
keen to understand psychological treatments, and to find out what they entail, and the diverse 
approaches that they adopt. Such exposure to ideas, and understanding how psychological 
interventions are actually conducted, is an important first step for basic researchers to start to 
formulate valuable research questions. It would therefore be desirable, where possible, for 
basic researchers to play a more active role in the supervision of research projects of clinical 
psychology trainees, and vice versa. Encouraging joint doctoral supervision (whether for 
research or clinical students) between basic researchers and clinical psychologist PIs would 
be a simple and valuable step in the right direction in this regard. Returning to our Australian 
example above, at UNSW Sydney, combined clinical / PhD students often conduct their PhD 
research under the supervision of basic researchers (e.g., behavioural neuroscientists) and test 
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questions with clear clinical relevance (e.g., on topics such as fear extinction, drug addiction), 
concurrent with completing their clinical training program. Such a model of supervision 
facilitates a broad training experience and a unique opportunity for mentorship from both 
clinical supervisors and basic researchers.    
 
Mixing and mingling - the role of conferences 
Finally, even amongst those clinical psychologists who do enter academia, few forums exist 
for exchanging ideas with researchers from other disciplines, as the journals they read and 
conferences they attend are typically discipline-specific (with some notable exceptions e.g. 
the annual MQ: Transforming Mental Health annual science meeting; a recent meeting on 
neuroscientific research into psychological treatments arranged by the European College of 
Neuropsychopharmacology:https://www.ecnp.eu/publications/presidents_blog/April%202016
.aspx; and the annual meeting of the German Association for Psychiatry, Psychotherapy and 
Psychosomatics: https://www.dgppn.de/). However, some clinical psychologists and 
neuroscience researchers have started to work together to produce new ideas for intervention. 
A good example is the adoption of ideas from the literature on the neuroscience of 
reconsolidation – the modification of old memories during their reactivation - in the 
formulation of new treatment approaches for PTSD260. Several studies have tested the 
possibility that reactivated memories could be disrupted through pharmacological 
intervention with propranolol261, 262, with some preliminary indications of positive effects. 
Other studies have tested whether the reconsolidation of established memories can be 
disrupted using simple psychological interventions based on cognitive science, with 
promising results. Engaging in a simple visuospatial task (the computer game Tetris) 
following memory reactivation was shown to substantially reduce subsequent intrusive 
memories of experimental trauma63. Although this line of research requires considerable 
further work to demonstrate robust clinical efficacy263, 264 (see Part 6, Trials), it is an 
intriguing example of the type of cross-pollination of ideas between basic and clinical 
research that holds promise to lead to improved treatments in the future. Other good 
examples are to be found in the development of new psychological interventions for 
anhedonia (see Panel 16). 
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In the 1950s and 1960s, the development of new psychological interventions transformed the 
landscape of mental health treatment, creating effective treatments based on novel, 
empirically testable models. Inspired by ideas drawn from cognitive psychology and 
behavioural neuroscience, the interventions developed through the collaborations of previous 
generations of basic researchers and clinicians have become today’s treatments of choice. 
Despite these successes, there is still great room for improvement as response to 
psychological interventions is highly variable; however, in recent decades the fruitful 
interaction between those who deliver psychological interventions and those who conduct 
basic research has waned. This gap impedes innovation in the development of new 
psychological treatments, both because basic researchers do not understand what 
psychological interventions entail, and because clinicians are not familiar with relevant 
advances. Above, we have outlined a number of concrete proposals with the aim of bridging 
this gap: these have in common the fostering of much more extensive interdisciplinary 
interaction and dialogue than currently exists (Panel 18). Through taking these steps, the next 
generation of clinicians and researchers will be better equipped than their predecessors to use 
new knowledge to drive the development of novel and more effective psychological 
treatments and preventative strategies that are needed to improve mental health outcomes. 
 
Panel 17.  Example Directions for the Future of Training and Links between Clinical 
and Basic Science 
 Opportunities for integrated clinical and academic training in psychology, through 
extended programmes, targeted at those clinicians with the greatest research 
potential 
 Training for basic researchers in psychological treatments, including hands-on 
experience of techniques, and interactions with clinicians, so that they can 
formulate research questions that are relevant to psychological interventions 
 An expectation of interdisciplinary research for psychological treatment 
researchers, including co-supervision of the research component of professional 
qualifications by clinical and non-clinical PIs  
 Provision of “next steps” seminars focused on academic training as a standard part 
of mental health clinical training programmes 
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 Better dissemination of research internship and doctoral funding opportunities for 
clinical psychologists, such as provided by the Society for a Science of Clinical 
Psychology (http://www.sscpweb.org/) 
 Training programmes on which clinical psychology, psychiatry and basic research 
trainees have the opportunity to learn alongside each other 
 High-level interdisciplinary meetings between basic researchers, clinical 
psychologists and psychiatrists, including forums in which practitioners can 
propose questions that they think are important to basic scientists; with tangible 
outcomes such as papers, grant applications, and implementation work 
 Use of the continuing professional development framework to enhance the 
understanding of basic science understanding among psychological treatment 
practitioners 
 
 
Part 8 Whom should we treat for what and with what? Embracing the complexity of 
mental health conditions from personalised models to universal approaches 
Introduction 
Most theoretical models and evidence-based psychological treatments have typically been 
derived for categorically defined specific mental health disorders, such as major depressive 
disorder, social phobia, or posttraumatic stress disorder. Leading clinical guidelines 
recommend specific treatments for each mental health disorder, usually categorically defined 
by symptomatologye.g.265,266. However, the reality of mental health conditions is more 
complex, and characterised by an enormous individual variety. Heterogeneity in 
symptomatology across mental health conditions is very common267 and many individuals 
suffer from more than one mental health disorder (i.e., co-morbidity268, 269). Many more have 
sub-syndromal symptoms of other conditions, and may have symptoms that shift between 
disorders over time. Mental health researchers – and those in psychological treatment 
research specifically - need to embrace the complexity of mental health disorders to make 
progress in reducing the burden of these disabling conditions. The complexity of mental 
health disorders is a challenge for research and clinical practice. Solutions to complexity of 
mental health disorders include both highly individualized ‘personalised’ approaches as well 
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as ‘universal’/‘transdiagnostic’ approaches that target common mechanisms. More studies are 
needed to examine whether these approaches improve the effectiveness of treatments for 
mental health disorders.  
Why are mental health disorders so complex?  
Unlike most areas of medicine, mental health disorders are defined predominantly by their 
symptoms. Lack of knowledge about aetiology contributes to this approach. Symptoms are 
often considered as manifestations of an underlying latent factor (e.g., sad mood and loss of 
interest is caused by an underlying Major Depressive Disorder, MDD). However, these 
symptoms may not (only) serve as output from ‘underlying’ processes, but the symptoms can 
mutually reinforce one other as presumed by the network approach270. For example, in 
depression, insomnia might lead to concentration problems, which in turn might cause 
sadness and loss of pleasure, which in turn might lead to fatigue, feelings of guilt and suicidal 
ideation, resulting in the full syndrome of MDD. Thus, it is uncertain whether these 
symptoms are indeed manifestations of an underlying factor270. 
Mental health conditions are dimensional in nature, yet most mental health 
researchers use a categorical model to study the effects of treatments. The Diagnostic and 
Statistical Manual of Mental Disorders-5 (DSM-5271) is a categorical nosology for 
classification, to detect for instance a depressive episode and to study the effects of a 
disorder-specific treatment for depression such as behavioral activation. In the last few years, 
initiatives have been taken, for instance by the RDoC initiative 272, to stimulate research on 
dimensions of observable behavior and neurobiological measures instead of categorical 
diagnostic criteria of mental health disorders (see Part 1). 
An additional complexity factor is individual differences at the level of 
psychopathology. Studies using network analyses have yielded new insights in individual 
variation of psychopathology267, 273. These studies indicate that while for some the transition 
from feeling healthy to fully depressed can be abrupt (categorical) in case of a strongly 
connected network of symptomatology, for others, for example individuals with a weakly 
connected network of symptoms, external stressors (such as not being able to pay rent) may 
lead to an increase in symptomatology - but these symptoms gradually decrease after the 
stressor is gone274. This could also be explained by a dimensional model of psychopathology; 
that is, individuals with strongly connected networks might be the individuals with higher 
 
 
80 
 
 
levels of neuroticism. It is unclear whether these individual differences can be explained by 
an underlying dimensional mechanism or categorical disorder. 
Mental health conditions are complex to study due to the interplay between individual 
emotions, cognitions, and physiology (and other factors) and their interactions with the 
environment, which change over time (see Part 1 for the differentiation of mechanisms 
responsible for onset versus mechanisms that are responsible for maintenance of 
psychopathology), and might also change as a consequence of suffering from a mental health 
condition. For instance, in depression, major life events (such as the death of a loved one) are 
consistent risk factors for onset of the first episode, while less stressful events (for instance 
getting a minor traffic ticket) are sufficient to trigger a subsequent depressive episode for 
individuals who have experienced one or two previous depressive episodes277. Enormous 
individual differences have also been found in emotional fluctuations – an important 
component of many mental health disorders - and how emotions change over time within 
mental health disorders275. 
Further, at least 45% of people suffering from mental health disorders have more than 
one disorder, i.e., co-morbidity (see Panel 18), while many more have sub-syndromal 
symptoms of other conditions268. The lifetime co-morbidity of common mental health 
disorders (i.e., anxiety disorders with major depressive disorder) rises up to 73%269. The 
Global Burden of Disease Study 2013  estimated that co-morbidity for acute and chronic 
diseases and injuries for 188 countries between 1990 and 2016, including co-morbidity of 
mental health conditions, has risen substantially278. Co-morbidity is consistently associated 
with a greater demand for professional help, a poorer prognosis, greater interference with 
everyday life, and higher suicide ratese.g. 281, 282. Better understanding of co-morbidity is 
crucial for knowledge on etiology and to improve psychological treatments for all mental 
health disorders.  
Heterogeneity and co-morbidity have been considered in some fields287, 289. 
Dimensional models have been proposed to explain co-morbidity, and mostly suggest shared 
factors for the concurrent disorders (such as neuroticism291), and some dimensional models 
add specific factors that differentiate among disorderse.g.293. For instance, the dimensional tri-
level hierarchical model of anxiety and depression includes a shared higher level factor for 
anxiety and depression (i.e., general distress), two additional factors that are at an 
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intermediate level in terms of specificity for anxiety and depression (i.e., anxious-misery and 
fears that explain covariation in positive affect, anhedonia, sad mood and social fears and 
fears to explain covariation in social fears, fears of specific stimuli, fear of interoceptive 
sensations, and agoraphobic fears), and five additional specific unique factors for depression 
and anxiety disorders (depression, fears of specific stimuli, anxious arousal, social fears and 
interoceptive/agoraphobic fears)294. As shown in Figure 5, the dimensional tri-level 
hierarchical model of co-morbidity between MDD and generalized anxiety disorders 
according to this model I (as indicated by the black boxes and black lines) is explained by 
general distress, and at an intermediate level by anxious-misery (e.g., anhedonia and 
depression), and at low level by specific factors (e.g., depression and anxious arousal). 
 
 
 
 
Figure 5. Co-morbid Major Depressive Disorder and Generalized Anxiety Disorder 
symptomatology explained by tri-level hierarchical model of depression and anxiety (based 
on294). Black boxes and lines represent factors and symptoms related to  the co-morbidity. 
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Alternatively, the network approach explains co-morbidity by spreading symptom 
activations. Co-morbidity is hypothesized to result from direct relations between symptoms 
of multiple disorders. That is, a symptom of one diagnostic category (e.g., MDD) can evoke 
other symptoms that in turn evoke symptoms of another diagnostic category (e.g., anxiety 
about several events, chronic anxiety/worry) 270. Thus, co-morbidity might be the result of 
shared symptoms across mental health disorders, so called bridge symptoms.  
Figure 6 represents an example of a dynamic network of MDD symptoms that 
mutually reinforce other symptoms of MDD and co-morbid Generalized Anxiety Disorder 
symptoms (adapted figure, based on270). Nodes represent symptoms and edges denote the 
presumed causal relationship between symptoms. Darker edges indicate a stronger 
relationship between the symptoms. For example, disturbed sleeping (symptoms of 
depression) could lead to fatigue and to concentration problems and irritability/agitation (so 
called bridge symptoms as indicated by red nodes) and other specific generalized anxiety 
disorder symptomatology. The bridge symptoms are criteria of MDD and Generalized 
Anxiety Disorder270, 295. Additionally, there might be individual differences in how co-
morbidity develops, resulting in many different paths to co-morbidity, depending on the 
individual and his or her environmente.g., 270, 295. The network approach does not explain why 
some individuals are more prone to co-morbidity (having more symptoms) than others. 
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Figure 6. Hypothetical dynamic network of Major Depressive Disorder (MDD) symptoms 
that mutually reinforce other symptoms of MDD and comorbid Generalized Anxiety Disorder 
Symptoms (GAD, adapted from270). Nodes represent symptoms and edges denote the causal 
relationship between symptoms. Darker edges indicate a stronger relationship between the 
symptoms. Red nodes are bridge symptoms of MDD and GAD. 
 
Both the network model and the dimensional (hierarchical) models (for instance 
dimensional underlying factors like neuroticism or general distress) might contribute to the 
explanation of mental health disorders, including co-morbidity. They emphasize the necessity 
to translate group findings to the individual struggling with mental health problems. The role 
of symptoms, individual differences in symptoms and emotions and potential underlying 
mechanisms as maintenance factors in mental health disorders are key elements to study.   
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Panel 18. What is Meant by Co-Morbidity, Disorder-Specific versus Transdiagnostic 
Treatment, and Personalised Treatment Approaches? 
 Co-morbidity: two or more mental health disorders that are present during the same 
period of time (concurrent co-morbidity) or that are present during one’s life 
(lifetime co-morbidity)  
 Disorder-specific treatment: a treatment that has been developed and evaluated for 
a specific mental health disorder 
 Transdiagnostic/universal treatment: the use of similar treatment approaches across 
a range of symptoms/mental health disorders that target the presumed underlying 
shared maintaining mechanisms296  
 Personalised treatment: optimize the most efficient and favorable response to 
treatment based on individual’s unique characteristics and/or presumed underlying 
mechanisms 
  
Personalised models of mental health conditions 
Although some disorder-specific treatments yield positive effects on co-morbid disorders as 
well (for instance CBT for specific anxiety disorders also reduce depressive 
symptomatology297), there is certainly room for improvement in terms of treatment outcomes 
for people with mental health disorders, including individuals with co-morbid mental health 
conditions.  
Research should embrace the complexity of mental health disorders to make further 
progress in psychological treatments research. One way forward is to study both inter- and 
intra-individual differences. Experience sampling method or ecological momentary 
assessment can be used to develop personalized models of psychopathology298. Experience 
sampling method refer to a collection of research methods by which a client repeatedly 
reports on symptoms, affect, behaviour, and cognitions close in time to experience and in the 
clients’ daily life, for instance by using an application on a mobile phone (see Part 5, 
Technology). Given that experience sampling method gather numerous assessments for each 
individual, individualised analyses can generate an individualised model on the dynamics of 
the network of psychopathology for each person. Hereby, for instance, the centrality (or the 
strength) of a specific symptom or mechanism for one specific person can be defined (e.g., 
loss of interest may be a central symptom for one individual with MDD, while for another 
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individual a central symptom could be sad mood)298. This would offer new insights into 
mental health disorders and personalised models of psychopathology. Systematic reviews 
have stressed the value of experience sampling method for assessing symptom fluctuations 
and interactions over time in anxiety disorders299, depressive disorders300, and substance 
use301. Studying transient processes of emotions, cognitions, symptoms and stress (and other 
relevant factors) in daily life can be done in prospective studies, as well as in experimental 
studies, such as a RCT (see Part 6, Trials). For instance, alongside a RCT of the effectiveness 
of three relapse prevention treatments in depression, an ecological momentary assessment 
study was incorporated in a subset of participants who had remitted from recurrent 
depression. This assessed participants’ emotions, cognitions, symptoms and imagery-based 
processing ten times a day, three days a week, for eight weeks using the “Imagine your 
mood” Application on a mobile phone302. Given these ecological momentary assessment 
studies are self-report questionnaires, it might be useful to add physiological and behavioural 
measures to such investigations.  
Personalised treatment approaches 
Research on personalised models might disentangle the complexity of mental health 
conditions, including co-morbidity, and optimise psychological treatments (see Panel 18). 
The goal of the personal medicine approach is to optimise the response to treatment based on 
an individual’s unique characteristics (ranging from genetic and neurobiological factors to 
symptoms) and underlying mechanisms (see Panel 18). Ecological momentary assessment 
might improve our insight into the specific diagnosis303,304 and offer valuable information that 
might improve patient-treatment matching. For instance, assessing daily fluctuations in 
positive and negative emotions using experience sampling method  in depression predicts 
response to treatment in depression305. Assessing individual change over time in emotions 
(and other processes) while undergoing therapy (for instance in the context of an RCT) might 
offer valuable empirical information on patterns of change and mechanisms of change during 
treatment.  
An alternative route to improve patient-treatment matching is to use a machine 
learning approach to identify characteristics of the individual, based on group-based studies, 
which predict differential response to existing treatments using methods to transform 
predictive information for a specific person. A recent demonstration is the computation of a 
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Personalised Advantage Index score306 comparing psychological versus pharmacological 
treatments for depression. Future studies should examine whether treatment matching can be 
improved for individuals with comorbid mental health disorders. Related approaches include 
clinical risk scoring, as currently used within the medical field307. For example, treatments for 
lung cancer are further improved by molecular testing for targeted therapies that can 
overcome resistance to first-generation drugs308.  Within the field of mental health conditions, 
we need more studies to examine the relevant variables for these index scores to optimize 
patient-treatment matching and incorporate the help of, for instance, machine learning.  
In addition, as described in Part 1 (Mechanisms), research on mechanisms of 
psychological treatments might reveal crucial moderators of treatment outcome that leads to 
better patient-treatment matching, such as a biological marker (for instance larger effects of 
an attentional bias training in anxiety disorders for the group of individuals with a specific 
polymorphism of the serotonin transporter gene 5-HTTLPR)48. 
Apart from enhancing patient-treatment matching, feedback to the clinician and the 
patient on daily fluctuations might be used to adapt treatment and thereby improve treatment 
outcome(s). Feedback on daily fluctuations of change within a person might enable us to 
adapt the interventions immediately within the sessions by giving real-time feedback on the 
progress to the clinician as well as the patient277. For instance, an RCT in 102 depressed 
patients showed that the efficacy of pharmacological treatment could be enhanced by adding 
experience sampling method -derived feedback on personalized patterns of positive affect to 
the clinician and the patient309. Collecting ecological momentary assessment data with 
comparable assessments within clinical settings on patterns of daily fluctuation of change 
over time within a person while undergoing treatment in a large population with mental 
health disorders (including outcomes after treatment) would be of great value (see Part 6, 
Trials). Mobile devices and applications could increasingly be used for person tailored, in-
the-moment interventions. In the future, researchers could make empirical data available to 
clinicians and patients, which may help them to work together on improving treatment 
outcome as a team. Close collaboration will be needed with computer science and 
mathematics, drawing on advances in these fields (for instance areas of complexity, 
dynamical systems, and dealing with big data). Future research is needed on the dynamics of 
symptom outcome rather than simply static assessments, for example using time series 
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analysis of daily mood data in bipolar disorder310, and using the same method within the 
context of RCTs. For now, more studies are needed to examine whether personalised 
treatments are indeed more effective than traditional treatments. A critical question for the 
coming years will be: can we personalise our psychopathological models to the level that we 
can adjust our treatment and thereby improve outcomes? (see Panel 19 and Part 6, Trials). 
One size fits all or a universal approach? 
Most traditional disorder-specific psychological treatments contain a package of several 
interventions that target underlying mechanisms of psychopathology (Part 1, Mechanisms of 
psychological treatments). Apart from traditional disorder-specific approaches and 
personalized approaches, the opposite – although not incompatible - approach is to consider 
commonalities between mental disorders and a more “universal” approach (see Panel 18). 
For example, adverse life events are consistent predictors of the onset of most mental health 
conditions311. A risk factor, for instance, stress sensitisation, might prove to be a valuable 
target for treatment, since changing sensitization might influence the other symptoms in the 
network as well, such as rumination or sleeping problems312. Alternatively, changing stress 
sensitization might reduce a latent factor (such as neuroticism) and thereby reduce 
symptomatology. We might focus research efforts on trying to identify universal underlying 
mechanisms across numerous mental health conditions, and try to target these mechanisms by 
universal interventions (see Panel 19). This transdiagnostic approach, for instance in eating 
disorders, has begun to yield very promising results 313, 314. 
Another example of a transdiagnostic psychological treatment approach is Barlow’s 
Unified Protocol for the transdiagnostic treatment of emotional disorders.315 This approach 
targets transdiagnostic mechanisms that are hypothesised to be responsible for the 
development and maintenance of psychopathology broadly, rather than addressing disorder-
specific mechanisms or symptomatology (especially studied in patients with a principal 
anxiety disorder). Within developments of this approach, a more personalised approach is 
included which assesses a personalised model for each patient’s dysfunction related to 
underlying mechanisms (profiling). The personal profile can be used to select additional 
interventions that are specific to the mechanisms underlying the patient’s symptomatology316. 
More studies are needed that examine whether these unified approaches are indeed more 
effective than traditional disorder specific treatments.  
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Finally, despite the apparent contrast between a personalised versus universal 
approach, we suggest that the research agenda embrace complexity, including co-morbidity, 
and consider both ends of the treatment spectrum – i.e., examine approaches which could 
offer cross-cutting universal treatment approaches and, if necessary, add disorder-specific 
interventions, alongside personalised treatment solutions (see Panel 18). Solutions to 
complexity of mental health disorders need to consider both highly individualised 
‘personalised’ approaches as well as ‘universal’ / ‘transdiagnostic’ approaches to target 
common mechanisms (see Panel 19).  
Panel 19. Example Directions for Future Research Regarding Complexities 
 Embrace the complexity of mental health disorders, including co-morbidity, by 
studying inter- and intra-individual differences in daily life: investigate individual 
processes of emotions, cognitions, symptoms and stress (and other relevant 
mechanisms) in prospective studies, as well as in experimental studies, such as a 
RCT 
 Study models that explain co-morbidity in mental health disorders and treatment 
approaches for co-morbid disorders  
 Investigate whether we can personalise our psychopathological models to the level 
that we can adjust treatments and thereby improve treatment outcomes 
 Investigate who we should treat with what: a disorder-specific treatment, a 
personalized treatment and/or transdiagnostic/unified treatment 
 Examine the effects of transdiagnostic/unified treatments for several mental health 
conditions including the co-morbid conditions in comparison to current evidence 
based disorder-specific treatments 
 
 
Part 9 Target: Suicidal behaviour: Protecting lives 
Introduction 
In this section we illustrate how many of the principles outlined earlier in the Commission 
could usefully be applied to the development, evaluation and implementation of treatments to 
reduce suicidal behaviour. Although the causes of suicide and suicidal behaviour are 
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complex, they are psychological phenomena at their core, as an individual who attempts 
suicide makes a decision to end their life. In the past 25 years, there have been significant 
advances in understanding who is most at risk of suicide and what factors increase this risk in 
some individuals but not in others. Moving forward, we can build upon the growing evidence 
base for psychological treatments to reduce the risk of suicidal behaviour. Despite these 
recent advances, however, there are key gaps in knowledge that require urgent attention. 
Addressing these gaps represents an excellent opportunity to develop more effective 
treatments that are replicable, more precise, and can reach those who are most vulnerable 
irrespective of who they are or where they live. 
Suicide and suicide attempts are the most tragic outcomes that result from our failure 
to effectively treat those with mental health problems. Suicide is a major public health 
concern: at least 804,000 people die by suicide globally each year317. As suicidal behaviour is 
a transdiagnostic phenomenon associated with a myriad of mental health problems, we 
believe that it is uniquely placed to be a ‘test case’ of how what we have learned elsewhere in 
this Commission can be applied to a specific problem.  
In addition to the personal tragedy associated with every death by suicide, the 
economic cost of suicide is enormous. For example, in EU countries, the average lifetime 
cost associated with a suicide is estimated to be approximately two million euros318 . 
Although the science of suicide research is still relatively new, there have been welcome 
advances in the understanding, treatment and prevention of suicidal behaviour in recent 
decades319.  These advances include a better understanding of the common risk factors for 
suicidal behaviour320-323, evidence that some psychological treatments reduce suicidal 
ideation and behaviour324-331 and growing evidence that public health interventions are 
associated with reductions in suicide330, 331. In this section, we describe the advances that 
relate to psychological treatments in more detail and identify a number of urgent calls to 
action (panel 20). Although we focus on psychological treatments, we should keep in mind 
how the principles outlined in this Commission can relate to the primary prevention of 
suicide.  
Although suicide most often occurs in the context of mental health disorder333, 334 
there is widespread recognition of the need to move beyond diagnostic categories in order to 
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explain and treat suicidal behaviour335. The central role of psychological factors in the 
aetiology and course of suicidal behaviour is now well recognized323. Arguably, suicide is the 
cause of death that is most closely related to psychological factors given that an individual 
makes a decision to end their own life323. Despite advances in our knowledge, our ability to 
predict who is most likely to kill themselves is limited because we do not have sufficiently 
specific markers of suicide risk. For example, although depression is the disorder most 
commonly associated with suicide risk, less than 5% of people treated for depression die by 
suicide323, 336 
New psychological models of suicide have been developed which have identified 
more proximal and specific markers of suicide risk337-343 (see also Part 1, Mechanisms). In 
addition to the theoretical importance of identifying proximal markers of the final common 
pathway to suicidal behaviour, proximal markers are vitally important clinically and should 
be treatment targets. Specifically, constructs including defeat, entrapment, belongingness, 
burdensomeness, future thinking, goal adjustment, reasons for living and fearlessness about 
death323, 339-341, 345 are among the key predictors of suicide attempts and should, therefore, be 
targeted in psychological treatments and suicide prevention activities more generally. To 
date, there has been insufficient focus on these suicide-specific psychological proximal 
markers. Moreover, we know little about which factors are responsible for the observed 
effectiveness of suicide prevention approaches (see also Part 1, Mechanisms). Psychological 
treatment trials for suicidal behaviour should routinely assess theoretically derived 
mechanisms (both psychological and biological) which may explain the treatment effect. A 
concerted focus on potential biomarkers, for example, salivary cortisol or the serotonin 
metabolite 5-hydroxyindoleacetic acid (5-HIAA), ideally tested in combination with other 
factors is also required347.  
Evidence for psychological treatments and suicidality 
Psychological treatments reduce suicidal ideation and suicide attempts,324, 326, 348 although 
there is little evidence that they have a marked effect on subsequent suicide349. Indeed, 
suicide rates stayed more or less the same or increased by more than 10% in half of the 172 
member states of the WHO between 2000 and 2012317. Most people who die by suicide are 
not in contact with clinical services in the 12 months before death, so until we expand the 
reach of psychological treatments beyond those already in contact with clinical services, it is 
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unlikely that they will have a direct impact upon national suicide rates. Given the complexity 
of the risk factors for suicide, multilevel interventions offer most promise350 and 
psychological treatments on their own will not make a sizeable dent in  suicide rates.  
Nonetheless, meta-analyses indicate that CBT is effective in reducing suicidal 
behaviour in adults, although not in adolescents327. A systematic review and meta-analysis of 
psychosocial interventions following self-harm in adults concluded that CBT “seems to be 
effective in patients after self-harm”, and specific studies provide support for dialectical 
behaviour therapy for individuals with borderline personality disorder 351 psychodynamic 
interpersonal therapy352 and mentalization-based therapy353 (although the need for 
replications of those which are single studies is noted). There are also recent efforts to 
determine whether the collaborative assessment and management of suicidality, a therapeutic 
framework for suicidality, is feasible and clinically effective354. The attempted suicide short 
intervention program (ASSIP), a brief integrated therapy and personalized letters 
intervention, showed encouraging findings in patients who have attempted suicide355.  
A meta-analysis of therapeutic interventions for suicide attempts and self-harm in 
adolescents concluded that therapeutic interventions are effective in reducing self-harm 
(when it is treated as a global category which includes suicidal and non-suicidal self-harm), 
but that the effects are weaker when suicidal and non-suicidal behaviour are examined 
separately356. The latter is consistent with the Cochrane review of interventions for children 
and adolescents who self-harm329. The review authors found only 11 trials, most of which 
were single trials, from which they concluded that therapeutic assessment, mentalization, and 
dialectical behaviour therapy “warrant further evaluation”13 (see also Part 4, Prevention). 
Treatments that target depression are not effective in reducing suicidal thoughts or 
attempts357. It is important to highlight that there is marked heterogeneity across treatment 
studies in the field, that many studies have relatively small sample sizes and that there is clear 
evidence of publication bias with no published studies reporting negative findings327. 
Replications of the existing treatments by independent groups are needed, as is the 
development of evidence-based assessment measures that are clinically useful in the suicide 
treatment research field (see also Part 6, Trials). 
The development, evaluation and implementation of psychological treatments for 
suicidality must be prioritised. Moreover, we need to determine the extent to which 
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psychological treatments are effective for different sociodemographic populations (males vs 
females, adolescents vs older adults, individuals from different ethnic backgrounds, etc.) as 
well as in different healthcare settings (e.g., primary/secondary care versus acute settings) 
and patient groups (e.g., psychiatric in- versus out-patients) (see also Part 8, Complexities). 
The sex-specific research is especially important, because more men die by suicide than 
women in all countries in the world317, but many more women participate in suicidal behavior 
treatment trials328. It is also not clear when it is optimal to deliver treatment interventions to 
reduce risk of future suicidal behaviour among those who have attempted suicide.  
Needless to say, psychological treatments are not a panacea. For those psychological 
treatments that are effective, overall the effect sizes have tended to be small328, 358, 399. Also, 
psychological treatments reach only a minority of people who take their own lives or who are 
suicidal (for many reasons including access and suitability). Given the established inequality 
gradient for suicide (people from lower socio-economic backgrounds are significantly more 
likely to die by suicide compared to their more affluent peers359), we need to challenge the 
structural inequalities (e.g., poverty) that contribute to the excess in suicide mortality evident 
in those from more socially disadvantaged backgrounds. 
Most suicides occur in low- and middle-income countries (LAMICs)317, so the extent 
to which treatments developed in high-income countries are generalizable to LAMICs needs 
very careful consideration (see also Part 2, Worldwide). When developing and evaluating 
treatment trials, consideration should be given to whether a tailored or modular approach is 
desirable/feasible, whether the treatment is principles-based or manualized, and whether the 
interventions account for different risk profiles and inequalities (see also Part 8, 
Complexities). More fundamentally (as noted in Part 1, Mechanisms), we need to re-focus 
our efforts to ensure that we understand the mechanisms responsible for treatment successes 
when they do occur (e.g., does prevention of suicide depend on changes in reward 
sensitivity?). Without an understanding of mechanisms, our ability to tailor, target, extend 
and replicate treatments is limited. An appreciation of mechanisms will help explain why 
treatments that are expected to be effective fail to be so.  
 
Challenges and opportunities for research   
The Calls to Action panel (see Panel 20) highlights the key challenges and opportunities for 
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suicide treatment research in the next decade and beyond. As those who are at imminent risk 
of suicide are usually excluded from treatment trials, we know little about which treatments 
may be effective in this patient group. Relatedly, most people who are suicidal do not receive 
treatment360, therefore, we need to better understand the barriers to help-seeking or accessing 
treatment. It may be that people in distress are reluctant to seek psychological or psychiatric 
treatment for fear of stigma. Organisations such as Headspace (https://www.headspace.org.au) 
in Australia (see also Part 2, Worldwide) offer a promising stepped care treatment model 
which is low in stigma, set in the community and provides family members (as well as 
friends and health professionals) with an avenue to seek help for a relative. Another challenge 
is that suicidal patients are difficult to maintain in treatment361, so in addition to better 
understanding the factors associated with disengagement, we need to maximize treatment 
delivery when patients are in healthcare settings. For example, innovative brief contact 
interventions225, 362, 363 have been shown to offer some promise in acute settings. They should 
be considered as adjuncts to existing treatments and may be effective in reducing the 
likelihood that individuals act on their suicidal thoughts362, 363. Although some public health 
suicide prevention interventions have adopted a multi-level approach and explored synergies 
(by delivering a combination of interventions364, 365), there are few examples of exploring 
synergies by combining different psychological treatments (see Part 3 on Combination 
Treatments).  Given the heterogeneity of those who attempt suicide or die by suicide, 
exploring the efficacy of treatment combinations is likely to be one fruitful avenue. However, 
potential iatrogenic effects ought to be monitored in such studies (as well as in mono-
treatment studies, see also Part 6, Trials). The potential for harm in psychological treatments 
has been highlighted in the Royal Australian and New Zealand College of Psychiatrists 
Guidelines for Deliberate Self-Harm358.  We also need to focus on mechanisms and target 
those in developing new treatment approaches. 
To facilitate the pooling of findings across different treatment studies, we urge suicide 
researchers to agree on a common set of core outcome measures (see also Part 6, Trials).  
There has been some movement in this regard in the USA325, however, an international 
consensus would be fruitful. To this end, it would be helpful to convene an international, 
interdisciplinary working group to agree such a set of measures. We also call for all 
psychological treatment trials to include a measure of suicidality as an outcome measure, 
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even in studies in which this may only be a secondary focus. Although suicidal behaviour 
occurs transdiagnostically, we need to consider the differential prevalence of suicidal ideation 
and behaviour across psychiatric categories and better understand why, for example, 
individuals with bipolar disorder are at particularly high risk of suicide366. Psychological 
treatments research needs to embrace the assessment of potential mechanisms to account for 
treatment efficacy, as well as determine the active ingredients of effective treatments for 
suicidality (see also Part 1, Mechanisms). 
We need to investigate the extent to which new technologies may be useful to engage 
so-called difficult to reach populations (e.g., men, adolescents)367. For example, could 
gaming technology be harnessed to engage young people in help-seeking and treatment? 
Mobile apps offer opportunities to monitor suicidal ideation and mood in real-time and have 
the potential to enhance our ability to identify (and intervene) when individuals are at their 
most vulnerable but must be developed with the same rigor as traditional means of 
psychological treatment delivery (see also Part 5, Technology). Arguably, the field of suicide 
prevention has not given due consideration to the cultural influences and pressures (e.g., 
depictions of masculinity) on men and women. Given the scale of male suicide, it is vital that 
we better integrate such factors into our understanding of suicide risk as well as suicide 
prevention efforts369-370.  
Those with lived experience of suicidal behaviour (e.g., individuals bereaved by 
suicide, and those with personal experience) should be involved in all stages of treatment 
development372. As we know relatively little about what protects vulnerable people from 
engaging in suicidal behaviour, research into potential buffering factors should be central to 
the development of treatment protocols (see also Part 4, Prevention). 
Finally, team science is key to the success of developing, evaluating and 
implementing psychological treatments to prevent suicide. As suicide is the end-product of 
the interplay between psychological, social, biological, clinical and cultural factors, 
interdisciplinarity should be the norm in psychological treatment research (see also Part 7, 
Training).  However, given that an individual makes a decision to end their life (in the 
context of a range of different risk factors), psychology needs to be at the centre of future 
developments in the field.  
To conclude, this is an exciting time to be working in psychological treatment 
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research for suicide, as we have the theoretical and empirical foundations for promising 
treatments.  In the next decade and beyond, however, we have to be innovative in our 
thinking and practice, to ensure that the promise of psychological treatments research is 
realized and leads to a reduction in suicidal ideation and suicide attempts. 
 
Panel 20. Calls to Action for Psychological Treatments Suicide Research 
 More large-scale psychological treatment trials (including psychotherapeutic 
and brief contact interventions) targeting suicidal ideation/behaviour are 
urgently required 
 Determine whether psychological treatments work for different 
sociodemographic populations (males vs females, adolescents vs older adults, 
individuals from different ethnic backgrounds etc) as well as in different settings 
(e.g., primary/secondary care versus acute settings), patient groups (e.g., 
psychiatric in- versus out-patients) and countries (e.g., low- middle-income 
versus high-income countries) 
 More rigorous investigation of those at imminent risk of suicide 
 Conduct replications of psychological treatments by independent groups 
 Agree on common measures of core outcomes (suicidal ideation and behaviour) 
and conduct multi-centre treatment studies and harness ‘big data’ techniques to 
determine whether psychological treatments can prevent suicide 
 Assess potential mechanisms derived from psychological theories hypothesized 
to account for treatment effects in all trials (risk and protective mechanisms) as 
well as moderators of the effects 
 Use techniques derived from experimental psychopathology to determine 
whether hypothesized mechanisms account for changes in symptoms or 
wellbeing (see Part 1, recommendations for identifying potential mechanisms) 
 Determine active ingredients of psychological treatments (including the role of 
therapeutic alliance) 
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 All psychological and social treatments (irrespective of whether suicidality is 
the target) should include a measure of suicidal thinking/behaviour which could 
be harvested in ‘big data’ analyses  
 Determine the barriers to treatment seeking in men, in particular 
 Investigate the extent to which new technologies may be useful to engage 
difficult to reach populations (e.g., men, adolescents) 
 Those with lived experience of suicidal behaviour (those bereaved by suicide, 
those with personal experience) should be involved in all stages of 
psychological treatment research 
 
Part 10 Trafalgar Square and The Empty Plinth - A space for active innovation and 
scrutiny of psychological treatments research of the future 
 
Inspecting ideas - and making space for ideas of the future  
Psychological treatments are highly effective for many patients but a large proportion either 
fail to respond to existing therapies, or the therapies that we have cannot reach them. To ‘see 
further’we need to innovate. To innovate, we need to generate ideas, and we need to engage 
in the critical inspection, progression as well as rejection of ideas, via the process of high 
quality, rigorous research.  
In the Introduction, we used the metaphor “The Fourth Plinth” in Trafalgar Square. A 
plinth here is a metaphor to make contemporary ideas visible and to give them critical 
consideration. Some pieces will be preserved for longevity, others may not. Particular 
psychological treatments or research ideas should not stand on a plinth forever, though some 
may stand the test of time. Rather, numerous ideas need to be generated, inspected and 
replaced over time, all within the context of a science-driven framework. Psychological 
treatment is a relatively young field, and the notion of innovation and turnover are critical 
parts of its future. 
 How might this work for psychological treatments? Let us consider the wide range of 
potential topics, how they could be selected, where they would be aired, how they could 
achieve visibility, and the need for a repeated cycle of this endeavour - with the ultimate aim 
to better air and debate the issues of our time in order to make a difference for mental health. 
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Topics could include both novel ideas or longstanding challenging topics. Novel issues could 
include recent findings that would benefit from constructive and rapid scrutiny (such as 
therapeutic approaches that emerge from the findings of pre-clinical studies, new ideas from 
sister disciplines, technology and new ethical issues, and so forth). Exciting new directions 
that emerge in these and other contexts should be clearly formulated, considered and reflected 
upon – and most importantly, need to be subjected to rigorous debate within and beyond the 
field, as well as empirical evaluation in the context of scientifically-sound studies such as 
well-controlled RCTs.  
 Open and constructive debate needs to be encouraged, without new ideas being too 
swiftly “smashed down” by tradition and vested interests in maintaining the status quo. On 
the other hand, new ideas and vogues in thinking (for example, fashionable new forms of 
therapy) must be scrutinised prior to being accepted and delivered in clinical practice. One 
problem for our field is the need to sustain the adoption of evidence-based treatments by 
practitioners, who may rather ignore the evidence and use the techniques for which they have 
a personal preference. For example, exposure is a theoretically driven treatment technique 
with an excellent evidence-base and for which there is a strong scientific understanding of the 
mechanisms that underlie its effectiveness84-88 (see Part 1, Mechanisms), however, in practice 
a substantial proportion of therapists do not use this effective therapeutic technique373. This 
reluctance and lack of uptake of empirically supported interventions, or aspects of them, is an 
issue that needs to be understood and rectified.  
The plinth metaphor also provides a way in which to question older ideas that we now 
take for granted, and yet would benefit from further examination. Many broader issues that 
affect the whole psychological treatment field require discussion (such as our diagnostic 
systems, the quantity of academic publications versus their capacity to deliver patient impact, 
funding issues that are specific to psychological treatments) as well as many issues that are 
relevant to science more generally - from reproducibility to open data. Psychological science 
is a young discipline compared to many other fields - emphasis on the history of 
psychological treatments over the last century could be of benefit here. There are parallels 
between some of our suggestions here and the ‘Science in Transition’ initiative in the 
Netherlands, which calls for a number of key reforms in science with the goal of scientists 
producing reproducible outcomes374,375. 
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How can topics be selected? In the art world, the “Empty Plinth” is an open 
competition from artists and subject to a review panel – the winner places an object up on a 
platform for viewing and discussion. For psychological treatments research, there could be 
equivalent competition/selection process of having specific calls for people to raise 
challenging ideas which catalyse progress. This will generate topics beyond that what we can 
imagine now, and potentially create a way to capture the concerns and questions of younger 
generations in our fields (e.g., why isn’t neuroscience being used more?), or those of 
researchers with several decades of experience (e.g., why have effect sizes for psychological 
treatments not improved?).  
The Empty Plinth approach could include a dedicated session at conferences and 
cross-disciplinary meetings, a type of journal article, in electronic media and so forth in areas 
which allow debate and scrutiny. The metaphor could be adapted to fit the range of outlets, 
and journal editors and conference organisers could be encouraged to provide space for this. 
In order to bring attention to the resulting ideas, an annual prize could be awarded for topics 
that have attracted attention and made constructive progress.  
The Plinth metaphor highlights the need for repetition in this process – so that novel 
psychological treatment ideas displayed in the Plinth will constantly be generated, tested, and 
disseminated (as indicated). This iterative process will not only encourage innovation, but 
will enable differentiation of those new treatments and ideas that will stand the test of time – 
and allow long held assumptions to be questioned in order to bring about progress. In some 
sense these are all processes that occur throughout the scientific process. But as we have 
argued throughout this commission, due to the scale of mental health problems, progress 
needs to speed up for psychological treatments research and borrowing an idea from the Arts 
may be just one way to catalyse this. 
The early stage of our field (compared to many other scientific disciplines, e.g., 
medicine, biology, physics) also offers opportunities. Mental health and psychological 
treatments provide critical, fascinating and demanding targets for research enquiry. Creative 
but realistic solutions require communication, and meaningful multidisciplinary 
collaborations among researchers and funding agencies, and some ‘blue skies’ thinking from 
outside the field. More psychological treatment researchers are needed across all disciplines – 
there remain a vast range of important questions that as yet have barely been addressed. This 
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poses a great opportunity for example for many early career scientists to make landmark 
contributions, and more should be encouraged to the field.  
Arguably, in some areas psychological treatment research has stagnated. Outcomes 
for many psychological disorders (including depression, obsessive compulsive disorder, 
schizophrenia and bipolar disorders) have not improved since the interventions were 
developed, and may even be falling376. There is an understandable current emphasis on 
increasing access to existing psychological treatments98 given the large unmet need and 
changing models of service delivery5,93,378,379. There is, however, an equally strong need to 
develop innovative new psychological treatments for the large proportion of people who do 
not engage with or respond to existing interventions, or who relapse after a seemingly 
successful course of treatment. The proportion of people who fall into one of these categories 
varies by disorder, age group and research study, but can be considered to be at least 50%380, 
381. We also see a pressing need for multiple solutions, given the scale of the challenge before 
us. There is clearly value in a range of approaches, including the dissemination of evidence-
based therapies, initiatives to reduce stigma, and increasing the accessibility of evidence-
based psychotherapies. So whilst we see the need for a multi-pronged approach, we argue 
that the development of new therapies is one of the most promising approaches - given the 
scale of the problem of mental health disorders from a public health perspective. 
.  
 
What factors might foster stagnation and what innovation? Branding, communication 
and funding 
  
One obstacle to innovation in the field of psychological treatment research is 
‘branding’ of psychological interventions, with the accompanying restrictions due to 
intellectual property issues. Such ‘branding’ prevents the dissemination and implementation 
of psychological therapies, and also stifles innovation by implying ‘ownership’ of an 
intervention383. A sustainable, not-for-profit model for the development of psychological 
interventions is an alternative and potentially better way forward. The increasing pressure 
from ‘knowledge transfer’ departments at Universities for branding for uniqueness by one 
research group needs to be resisted where useful in favour of developments in psychological 
 
 
100 
 
 
therapies that are more open, highlight shared common components, and are precisely 
described at a level at which they can benefit from examination by the wider the 
psychological treatment community. The issue is clearly complex due to concerns with 
regard to incentivising investment in psychological treatments from a range of sources, as 
well as the need for quality control within particular interventions. The development of 
‘citizen science’ has the potential to counteract branding and provide a fertile ground for 
innovation. Examples need to be developed and shared. 
As reflected in the previous Section 7 on training, is striking how the majority of 
psychological treatment researchers stick to what they know. Such adherence is rewarded by 
strong CVs, grant funding and an unparalleled deep knowledge of a field. However, it can 
also lead to insularity. Fields that are highly relevant to psychological treatments from not 
only neuroscience, maths and pharmacology (as discussed earlier in Section 1, Mechanisms), 
but a diverse range disciplines such as ‘medical geography’382 could help clinical researchers 
and practitioners think differently. Communicating with colleagues in other areas of science 
and bringing their learning into our psychological treatments has huge potential. Jointly 
reviewing advances in areas such as cognitive and social science to identify which 
innovations will be relevant to improving psychological therapies is entirely feasible. Such an 
approach has tremendous potential to facilitate the introduction of new, scientifically sound 
ideas into treatment. Innovation benefits from creativity – including taking ideas from one 
area and seeing if they apply to another for treatment benefits.  
Communication between clients, clinicians and across the health services as a whole 
needs improvement. Mental and physical healthcare services are typically entirely separate 
services with minimal overlap, despite their close relationship in terms of pathology, service 
use and cost to the health services around the world384. Improving communication between 
providers of these two services via shared training, resources or even co-location will be a 
fundamental step in innovation, with scope to yield significant benefits for the entire 
healthcare system. Drawing on multiple areas of expertise will be important; in particular, 
obtaining input from patients and carers – a topic that is receiving increasing attention385, but 
requires more.  
It is impossible to divorce the issues of innovation and improvement from those of 
dissemination and implementation. Innovations that stay localised will benefit some patients 
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but the impact will be minimal (see Part 2, Worldwide). Furthermore, the length of time from 
‘bench to bedside’ (currently estimated at 17 years, although some argue it will be quicker to 
develop psychological than pharmacological treatments3,386) will continue to be unacceptably 
high unless dissemination and implementation are part of the plan from the outset. 
Communication between stakeholders is essential to ensuring the impact of innovations. It is 
only through the development of meaningful networks that genuine collaborations can be 
built – such as joint training, joint conferences and joint funding. Such networks need to be 
funded appropriately for the stage of development, with basic researchers and clinicians 
having a bi-directional conversation, initially by email but then face-to-face in a relaxed 
atmosphere with time to think creatively, argue constructively and develop testable 
hypotheses.   
The role of funders in promoting or stifling innovation cannot be overemphasised. 
The NIMH’s influence on funding has been profound, and inclusion of an ‘other’ category on 
the RDoC387 so that researchers are not restricted to only studying the known has the 
potential to facilitate new ideas. While researchers understand that funding agencies have a 
tendency to be risk averse, the funding of high risk studies is fundamental to the development 
of new treatments. More support akin to the funding of psychological therapies for proof of 
concept studies in psychological therapies could be especially important to the field; the level 
of funding for mental health research internationally, and psychological treatments in 
particular is far too low: 388, 389 increased funding is essential for progress in order to take 
risks in new areas. 
Globally, within larger funding organisations, mental health is often subsumed with 
other diseases or with for example, neuroscience. Representation by people with mental 
health research experience can be thin. Genuine expertise in mental health is needed on the 
decision making bodies of the major funding bodies. Clearer representation of expertise in 
psychological treatments would also be of benefit. It would be useful to have a review of 
international funding organisations which address mental health, and to determine the extent 
to which psychological treatment research is included and accommodated.  Some charities 
fund research and this is of course welcomed, but unfortunately many smaller charities often 
do not have the capacity to conduct a rigorous research review process. The quality and 
impact of studies that fail to benefit from peer review and scientific support is often sub-
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optimal. Funding models whereby smaller charities supporting mental health research are 
supported by larger charities with regard to their commissioning and execution of research is 
likely to improve both the quality of research and value for money of the research project. 
The creation of a framework for peer review for mental health in general, and psychological 
treatment in particular – or even a possible outsourcing model for such processes – might 
help many organisations with funding initiatives in the area.  
 
How can we assess the effectiveness of our efforts? 
Our broad aim in undertaking this Commission was to identify ways in which research efforts 
have scope to improve mental health globally via advancements in the effectiveness and the 
global reach of psychological treatments. More specifically, we have outlined an agenda of 
some of the concrete areas in which we see real scope for improvements in treatment research 
and their delivery to translate to more effective interventions, and greater accessibility of such 
treatments, to individuals with mental health difficulties. Treatment protocols that more 
effectively treat, as well as prevent the onset of, mental disorders will in turn have a part to 
play among the many contributions needed to relieve the substantial worldwide burden 
imposed by mental ill health. 
Our capacity to assess in a tangible and meaningful way whether the goal of 
improving mental health treatments has in fact been achieved remains a challenge for the 
field. The initial indicator of success on this front is at the level of trial outcomes – i.e., to 
examine whether effect sizes indicate improved efficacy of novel and refined psychological 
interventions. In the longer term, meta-analyses will delineate whether newer treatment 
approaches have made substantial gains in terms of improved effectiveness – and thus in turn, 
contribute to reducing the prevalence and indeed the burden of mental health problems. In the 
more distant future, the findings of epidemiological studies that illustrate rates of prevalence 
over time will speak to the success of treatment and prevention approaches. We 
acknowledge, however, that ‘measurement’ in this domain is indeed complicated and 
ambitious; e.g., changes in our diagnostic classification systems complicate these types of 
comparisons over time. We therefore see a need for research on how to define and quantify 
burden. We see scope for further progress to be made in not only examining prevalence rates, 
but also by investigating improvements in the functional impact of mental disorders, from 
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impairments in social and occupational functioning through to quality of life (e.g., using 
instruments such as WHODAS 2.0390). Such a suggestion chimes with our earlier 
acknowledgement of the value of expanding conceptualizations of mental health beyond the 
notions of disease and infirmity to outcomes with broader functional relevance (e.g., an 
individual’s capacity to adapt, self-manage, etc; see Introduction). 
 
Innovation to create new treatments. What ideas can we cast on the plinth in the first 
round?  
Increasing access to existing effective psychological treatments is a priority, but it is equally 
important to invest in innovations that will energise the field of psychological treatment 
research and improve therapeutic outcome5, 93. There are many books and journal articles 
dedicated to the issue of innovation, and even an entire journal devoted to this topic 
(‘Healthcare: The Journal of Delivery Science and Innovation’), which commenced in June 
2013. It is clear that innovation is a challenging area and that what is presented as innovation 
can often be seen as ‘old wine in a new bottle’. Innovation needs to be put in its historical 
context so that existing ideas are not repackaged with enthusiasm as an innovation391. As said, 
we need to engage in the critical inspection, progression as well as rejection of ideas via 
research; that is, to celebrate a metaphorical plinth with replenishing ideas, rather than to 
imagine therapy-brand statues which stand for ever. One approach is to change the nature of 
the questions are asking. Here we begin with two examples. 
 
What matters to patients?  
Arguably, most clinical research has focussed on single diagnoses despite the fact that many 
patients experience multiple co-existing disorders392 (see Part 8, Complexity). Clinicians have 
guidelines for the treatment of specific diagnoses but almost no data to guide them with 
regard to evidence-based decision-making in cases where patients have common co-occurring 
disorders such as anxiety and depression. Patients’ difficulties can alternatively be considered 
in terms of the problem they are experiencing rather than in diagnostic terms, for example 
‘loneliness’, or ‘betrayal’393. Linking with social psychology and having a problem-based 
approach to the development of psychological treatments, rather than a disorder-based 
approach, is likely to lead to new ways of thinking about, and addressing, mental health 
 
 
104 
 
 
disorders, which was partly the intention of the RDoC initiative387. The value to patients of 
focussing on functioning (rather than disorder) would benefit from more attention. Such 
approaches may increase engagement in and the acceptability of therapies, but would still 
have their challenges in terms of agreeing operationalised definitions of the problem, as well 
as ensuring that such difficulties were impacting on people’s lives in ways they value and 
could be viewed within a psychological framework.  
 
What matters to researchers?  
Many things matter to researchers - but most scientists become curious about what does not 
work, not just what does. Data that do not obey ‘the rules’ are essential to scientific progress. 
For psychological treatments research, defining non-responders, identifying which people 
relapse, as well as those who fail to engage in treatment - are all necessary and critical steps 
that will enable our field to progress381. Conducting a thorough and focused analysis of the 
characteristics of those individuals who do not respond to existing treatments, and having 
dedicated funding for such research, are priorities that would have a positive impact and 
would bring generalizable benefits to existing as well as new treatments.  
 
What next?  
We see mental health as a significant global challenge, but at the same time recognise that in 
current times we are faced with an array of pressing priorities that demand global attention 
and action; including but in no way limited to climate change, international conflicts, famine, 
and the displacement of millions of people from their home country. Notwithstanding the fact 
that many such significant problems exist in our world today, in the domain of mental health, 
we call for increased research efforts in order to evolve psychological treatments, so that 
more effective interventions will serve as an important part of our armoury of approaches 
needed to make a significant impact upon the burden of mental disease worldwide. 
We acknowledge that our call for developments in psychological treatments for mental health 
problems is but one endeavour in the context other timely such initiatives. For example, 
Wykes et al.394 recently laid out six key priorities for a mental health research agenda for 
Europe and worldwide. Mental health is increasingly being recognised as a domain in which 
we need to move forward on a global scale. Furthermore, psychological interventions can be 
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applied not only to mental health problems, but have been increasingly utilised across a range 
of areas; for example, in promoting health behaviour change, managing the psychological 
aspects and impact of physical health problems (e.g., pain management and somatic concerns, 
psycho-oncology), instituting organisational change, to name just a few.  
 
Clinicians, researchers, patients, carers, funders, commissioners, managers, policy-
planners, ‘change’ experts and the wider public all have a part to play in innovating 
psychological therapies and a focus on any one of the above ideas presented in this paper has 
the potential to bring about dramatic and much-needed improvements. More ideas will be 
needed. This is not a specific road map -  we need to rethink across relevant areas what 
matters to gain traction. Innovations arising from thoughtful effort have genuine potential to 
transform the science and practice of psychological therapies, as well as the lives of all of 
those affected by mental health problems.  
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